Dihydrotetrabenazine for use in the treatment of movement disorders

The combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine effectively treats movement disorders by enhancing therapeutic efficacy and reducing side effects, addressing the unclear isomer responsibility in tetrabenazine's activity.

JP7595630B2Active Publication Date: 2024-12-06ADEPTIO PHARMA
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022194948
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-06-06
Filing Date
2022-12-06
Publication Date
2024-12-06
Estimated Expiration
2038-03-29

AI Technical Summary

Technical Problem

The exact stereoisomer responsible for the therapeutic properties of tetrabenazine in treating movement disorders such as Tourette syndrome has not been clearly identified, with previous studies suggesting a role for the (+)-α-dihydrotetrabenazine isomer without conclusive evidence.

Method used

A combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine is found to be effective in treating movement disorders, with the (-)-α-dihydrotetrabenazine isomer surprisingly contributing to the efficacy when administered alongside the (+)-isomer, potentially binding to proteins other than VMAT2 to mediate hyperkinetic movement disorders.

Benefits of technology

The combination of both isomers provides enhanced therapeutic efficacy in reducing locomotor activity and treating conditions like Tourette syndrome, Huntington's disease, hemiballism, senile chorea, tic disorders, and tardive dyskinesia, with lower side effects and improved VMAT2 blockade control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595630000014
    Figure 0007595630000014
  • Figure 0007595630000015
    Figure 0007595630000015
  • Figure 0007595630000016
    Figure 0007595630000016
Patent Text Reader

Abstract

The present invention provides a formulation for treating movement disorders such as Tourette's syndrome. [Solution] A unit dosage form containing 5 mg to 80 mg of (+)-β-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the (+)-β-dihydrotetrabenazine is accompanied by 20% or less by weight of any other dihydrotetrabenazine isomer relative to the (+)-β-dihydrotetrabenazine.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of combinations of (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and / or (+)-β-dihydrotetrabenazine for the treatment of movement disorders such as Tourette's syndrome. [Background technology]

[0002] 2. Background of the Invention Movement disorders can generally be divided into two categories: hyperkinetic and hypokinetic. Hyperkinetic movement disorders are caused by increased muscle activity and can result in abnormal and / or excessive movements, including tremors, dystonia, chorea, tics, myoclonus, and stereotypic behaviors.

[0003] Hyperkinetic movement disorders are often psychological in nature and arise through inappropriate regulation of amine neurotransmitters in the basal ganglia.

[0004] A particular hyperkinetic movement disorder is Tourette's syndrome, which is an inherited neurological condition characterized by multiple physical and vocal tics. Tics are usually repetitive but random physical movements or vocal noises. Vocal tics can take a variety of forms and include repeating one's own words, other people's words, or other sounds. Onset usually occurs in childhood and continues into adolescence and adulthood.

[0005] Tics associated with Tourette's syndrome can be temporarily suppressed, but affected patients are usually only able to suppress them for a limited period of time. There is still no effective treatment to cover all types of tics in all patients, but specific medications have been developed to suppress tics.

[0006] Dopamine receptor antagonists are known to exhibit the ability to suppress tics in Tourette's syndrome patients, and a number of dopamine receptor antagonists are currently used to suppress Tourette's tics, such as fluphenazine, haloperidol and pimozide.

[0007] The vesicular monoamine transporter type 2 (VMAT2) is a membrane protein involved in the transport of monoamine neurotransmitters, such as dopamine, serotonin, and histamine, from the cytosol to synaptic vesicles. Inhibition of this protein prevents presynaptic neurons from releasing dopamine, resulting in depletion of dopamine levels in the brain.

[0008] VMAT2 inhibitors can be used to treat the symptoms of Tourette's syndrome.

[0009] Tetrabenazine (chemical name: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-one) has been used medicinally since the late 1950s. Initially used as an antipsychotic, tetrabenazine is now used to treat hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tics, tardive dyskinesia, and Tourette's syndrome (see, e.g., Jankovic et al., Am. J. Psychiatry (1999) Aug;156(8):1279-81 and Jankovic et al., Neurology (1997) Feb;48(2):358-62).

[0010] The primary pharmacological action of tetrabenazine is to decrease the supply of monoamines (e.g., dopamine, serotonin, and norepinephrine) in the central nervous system by inhibiting the human vesicular monoamine transporter isoform 2 (hVMAT2). The drug also blocks postsynaptic dopamine receptors.

[0011] The central action of tetrabenazine is very similar to that of reserpine, but differs from it in that it lacks activity at the VMAT1 transporter, which means that tetrabenazine has less peripheral activity than reserpine and therefore does not produce VMAT1-associated side effects such as hypotension.

[0012] Tetrabenazine is an effective and safe drug for the treatment of various hyperkinetic movement disorders and, in contrast to typical neuroleptics, has not been shown to cause tardive dyskinesia. Nevertheless, tetrabenazine exhibits a number of dose-related side effects, including depression, parkinsonism, drowsiness, nervousness or anxiety, insomnia, and in rare cases, neuroleptic malignant syndrome (see, for example, the introductory section of WO2016 / 127133 (Neurocrine Biosciences)).

[0013] The chemical structure of tetrabenazine is: [ka]

[0014] This compound has chiral centers at the 3 and 11b carbon atoms and can therefore theoretically exist in a total of four isomeric forms, as shown below. [ka]

[0015] The stereochemistry of each isomer is defined using the "R and S" nomenclature developed by Cahn, Ingold and Prelog (see Advanced Organic Chemistry, 4th Edition, by Jerry March, John Wiley & Sons, New York, 1992, pages 109-114). In this patent application, the designations "R" or "S" are given in the order of the carbon atom position number. Thus, for example, RS is a shorthand designation for 3R,11bS. Similarly, when there are three chiral centers, such as in dihydrotetrabenazine described below, the designations "R" or "S" are listed in the order of carbon atoms 2, 3 and 11b. Thus, the 2R,3S,11bS isomer is abbreviated as RSS, etc.

[0016] Commercially available tetrabenazine is a racemic mixture of the RR and SS isomers, which appear to be the most thermodynamically stable isomers.

[0017] Tetrabenazine is somewhat less bioavailable and more variable. It is extensively metabolized by first-pass metabolism, and little or no unchanged tetrabenazine is typically detected in the urine. At least some of the metabolites of tetrabenazine are known to be dihydrotetrabenazine, which is formed by reduction of the 2-keto group in tetrabenazine.

[0018] Dihydrotetrabenazine (chemical name: 2-hydroxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxybenzo(a)quinolizine) has three chiral centers and can therefore exist in any of the following eight optically isomeric forms: [ka]

[0019] The synthesis and characterization of all eight dihydrotetrabenazine isomers has been described by Sun et al. (Eur. J. Med. Chem. (2011), 1841-1848).

[0020] Of the eight dihydrotetrabenazine isomers, four isomers, namely the RRR, SSS, SRR and RSS isomers, are derived from the RR and SS isomers of the parent tetrabenazine.

[0021] The RRR and SSS isomers are commonly referred to as "alpha (α)" dihydrotetrabenazines and can be referred to as (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, respectively. The α isomer is characterized by the trans relative orientation of the hydroxyl and 2-methylpropyl substituents at the 2- and 3-positions. See, e.g., Kilborn et al., Chirality, 9:59-62 (1997) and Brossi et al., Helv. Chim. Acta, vol. XLI, No. 193, pp 1793-1806 (1958).

[0022] The SRR and RSS isomers are commonly referred to as "beta (β)" isomers and can be referred to as (+)-β-dihydrotetrabenazine and (-)-β-dihydrotetrabenazine, respectively. The β isomer is characterized by the cis relative orientation of the hydroxyl and 2-methylpropyl substituents at the 2- and 3-positions.

[0023] Although dihydrotetrabenazine is believed to be primarily responsible for the drug's activity, there are no published studies to date that contain evidence demonstrating which of the various stereoisomers of dihydrotetrabenazine are responsible for its biological activity. More specifically, there are no published studies that demonstrate which stereoisomer is responsible for tetrabenazine's ability to treat movement disorders such as Tourette's syndrome.

[0024] Schwartz et al. (Biochem. Pharmacol. (1966), 15:645-655) described metabolic studies of tetrabenazine carried out in rabbits, dogs and humans. They identified nine metabolites, five of which were unconjugated and the other four were conjugated to glucuronic acid. The five unconjugated metabolites were α- and β-dihydrotetrabenazine, two oxidized analogues in which a hydroxyl group had been introduced at the 2-methylpropyl side chain, and an oxidized tetrabenazine in which a hydroxyl group had been introduced at the 2-methylpropyl side chain. All four conjugated metabolites were compounds in which the 9-methoxy group had been demethylated to give the 9-hydroxy compound.

[0025] The chirality of the various metabolites was not studied, and in particular there was no disclosure of the chirality of the individual α- and β-isomers.

[0026] Scherman et al. (Mol. Pharmacol. (1987), 33, 72-77) described the stereospecificity of VMAT2 binding between racemic α- and β-dihydrotetrabenazine. They reported that α-dihydrotetrabenazine has a 3-4-fold higher affinity for the chromaffin granule monoamine transporter than the β-isomer when studied in vitro. However, Scherman et al. did not disclose separation or testing of the individual enantiomers of α- and β-dihydrotetrabenazine.

[0027] Mehvar et al. (J. Pharm. Sci. (1987), 76(6), 461-465) reported a study on the concentrations of tetrabenazine and dihydrotetrabenazine in rat brain after administration of either tetrabenazine or dihydrotetrabenazine. This study showed that dihydrotetrabenazine, despite its greater polarity, is able to cross the blood-brain barrier. However, the stereochemistry of dihydrotetrabenazine was not disclosed.

[0028] Mehvar et al. (1987, Drug Metabolism and Distribution, 15:2, 250-255) described a study on the pharmacokinetics of tetrabenazine and dihydrotetrabenazine when tetrabenazine was administered to four patients suffering from tardive dyskinesia. Oral administration of tetrabenazine resulted in low plasma concentrations of tetrabenazine but relatively high concentrations of dihydrotetrabenazine. However, the stereochemistry of dihydrotetrabenazine formed in vivo was not reported.

[0029] Roberts et al. (Eur. J. Clin. Pharmacol. (1986), 29:703-708) described the pharmacokinetics of tetrabenazine and its hydroxy metabolites in patients treated for involuntary movement disorders. reported that tetrabenazine is extensively metabolized after oral administration, resulting in very low plasma concentrations of tetrabenazine, but much higher concentrations of the hydroxy metabolites. Although they did not describe the identity of the hydroxy metabolites, they suggested that the high plasma concentrations of the hydroxy metabolites may be therapeutically important (because the metabolites are known to be pharmacologically active moieties) and, in light of the disclosure in Schwartz et al. (ibid.), that combinations of cis and trans isomers (i.e., alpha and beta isomers) may be more therapeutically important than the parent drug.

[0030] Michael Kilbourn and coworkers at the University of Michigan Medical School have published a number of studies on the various isomers of dihydrotetrabenazine. In Med. Chem. Res. (1994), 5:113-126, Kilbourn et al. describe the use of (+ / -)-α-[11C]-dihydrotetrabenazine as an in vivo imaging agent for VMAT2 binding studies.

[0031] In Eur. J. Pharmacol (1995) 278, 249-252, Kilbourn et al. reported a competitive binding study with [3H]-tetrabenazine to test the in vitro binding affinity of (+)-, (-)-, and (+ / -)-α-DHTBZ. The binding assay gave Ki values ​​of 0.97 nM for (+)-α-dihydrotetrabenazine and 2.2 μM for (-)-α-dihydrotetrabenazine, thereby indicating that the (+)α isomer has a much greater binding affinity for the VMAT2 receptor than the (-)α isomer. However, no studies have been reported or concluded about the utility of either isomer in the treatment of movement disorders such as Tourette's syndrome.

[0032] In Chirality (1997) 9:59-62, Kilbourn et al. described studies aimed at identifying the absolute configuration of (+)-α-dihydrotetrabenazine, from which they concluded that it has the 2R,3R,11bR configuration shown above. They also referred to the papers by Schwartz et al. and Mehvar et al. discussed above as indicating that α- and β-dihydrotetrabenazine are likely to be pharmacologically active agents in the human brain, although they did not draw any definite conclusions regarding the precise stereochemical identity of the active metabolites of tetrabenazine.

[0033] In Synapse (2002), 43:188-194, Kilbourn et al. described the use of (+)-α-[11C]-dihydrotetrabenazine as an agent used to measure specific in vivo binding of VMAT receptors in an "infusion into equilibrium method." They found that (-)-α-[11C]-dihydrotetrabenazine produced homogeneous brain distribution, which is consistent with previous observations that this enantiomer has low VMAT affinity.

[0034] Sun et al. (ibid.) investigated the VMAT2 binding affinity of all eight dihydrotetrabenazine isomers. They found that all of the dextrorotatory enantiomers exhibited dramatically stronger VMAT2 binding activity than their corresponding levorotatory enantiomers, with the most active (+)-α-isomer being found to be the most active. However, Sun et al. did not study the relative efficacy of the individual isomers in treating movement disorders such as Tourette's syndrome.

[0035] WO2011 / 153157 (Auspex Pharmaceutical, Inc.) describes deuterated forms of dihydrotetrabenazine. Although many deuterated forms of dihydrotetrabenazine are shown, the application provides only sufficient information to enable synthesis of a few of the compounds shown. Racemic mixtures of d6-α-dihydrotetrabenazine and d6-β-dihydrotetrabenazine are disclosed, but these mixtures are not separated and the properties of the individual (+) and (-) isomers are not studied. Similarly, WO2014 / 047167 (Auspex Pharmaceutical, Inc.) describes many deuterated forms of tetrabenazine and its derivatives. Again, the individual (+) and (-) isomers of the deuterated forms of α- and β-dihydrotetrabenazine were not separated or studied.

[0036] It is clear that, until now, it has been unclear exactly which dihydrotetrabenazine isomer is responsible for the therapeutic properties resulting from administration of tetrabenazine. (+)-α-dihydrotetrabenazine has previously been hypothesized to be the metabolite of tetrabenazine that is primarily responsible for its therapeutic effect (WO2015 / 171802 Neurocrine Biosciences, Inc.), but this has not been experimentally demonstrated. Summary of the Invention [Problem to be solved by the invention]

[0037] Summary of the Invention As mentioned above, studies carried out by Schwartz et al. (see above) demonstrated that both alpha and beta isomers of tetrabenazine are formed as metabolites of tetrabenazine, however the exact stereochemical configuration of the alpha and beta isomers was not investigated.

[0038] Studies in human subjects conducted by the applicant and described in Example 1 below confirmed the findings of Schwartz et al. that the major metabolites of tetrabenazine are indeed α- and β-dihydrotetrabenazine. However, in contrast to what has previously been suggested, the primary metabolites produced upon administration of tetrabenazine are the (-)-α-dihydrotetrabenazine isomer, which is intrinsically active as a VMAT2 binder, and the (+)-β-dihydrotetrabenazine isomer, which is significantly less active than the (+)-α-dihydrotetrabenazine isomer.

[0039] Thus, in single-dose studies in adult males administered tetrabenazine, the C max The C values ​​for (-)-β-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine were 103 and 72.94 ng / ml, respectively. max The values ​​were 5.28 and 2.61 ng / ml, respectively. Area under the curve (AUC) values ​​for (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine, (-)-β-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine metabolites were 375.78, 305.84, 16.28 and 7.98, respectively. A similar distribution of metabolites was found when multiple doses of tetrabenazine were administered.

[0040] The data suggest that (+)-α-dihydrotetrabenazine is not primarily responsible for the therapeutic properties of tetrabenazine. Conversely, it appears that (+)-α-dihydrotetrabenazine may be responsible for a relatively minor contribution to the therapeutic properties of tetrabenazine.

[0041] The importance of preparing enantiomeric compositions for the treatment of the human and animal body is known. It is well known that enantiomers may have different biological properties, for example, one enantiomer is useful in the treatment of a particular disease or condition, and the other enantiomer is toxic or produces undesirable side effects. An example of this is the drug thalidomide, marketed as a sedative and also prescribed to pregnant women to treat morning sickness, but later, one enantiomer was found to cause birth defects in the children of women who were administered thalidomide during pregnancy.

[0042] According to FDA guidance on enantiomers, the use of drug substances and drug products should include stereochemically specific identity testing and / or stereochemically selective assay methods.

[0043] Even if one of the enantiomers is medically useful and the other is inactive and shows no side effects, it may still be advantageous to remove the inactive enantiomer in order to reduce the size of the dosage form administered to the patient. [Means for solving the problem]

[0044] Combination of (+)-.ALPHA.-dihydrotetrabenazine and (-)-.ALPHA.-dihydrotetrabenazine It has now surprisingly been found that the combination of (+)- and (-)-α-dihydrotetrabenazine is more effective in reducing locomotor activity in amphetamine-induced rats than (+)-α-dihydrotetrabenazine alone, despite the previously reported fact that (-)-α-dihydrotetrabenazine is a poor VMAT2 inhibitor.

[0045] It has also been shown that both racemic and scalemic (ie, non-racemic) combinations exhibit enhanced potency.

[0046] Studies have confirmed the inactivity of (-)-α-dihydrotetrabenazine in treating movement disorders when administered alone (see Example 2, Study 1). However, it has been unexpectedly found that when (-)-α-dihydrotetrabenazine is administered in combination with (+)-α-dihydrotetrabenazine, improved efficacy is observed compared to administration of the (+)-isomer alone (see Example 2, Studies 3 and 4). This improved efficacy is believed to be due to (-)-α-dihydrotetrabenazine binding to proteins other than VMAT2, which may play a role in mediating hyperkinetic movement disorders.

[0047] Based on research conducted to date, it is believed that combinations of (+)- and (-)-α-dihydrotetrabenazine are useful in the prevention or treatment of disease states and conditions for which tetrabenazine is currently used or proposed. Thus, by way of example and not limitation, the dihydrotetrabenazine compounds of the present invention can be used to treat movement disorders, particularly hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia, and Tourette's syndrome. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] Thus, in a first aspect, the present invention provides a pharmaceutical unit dosage form comprising (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine, or pharma-ceutically acceptable salts thereof, and a pharma-ceutically acceptable excipient.

[0049] Typically, the combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, is not administered with a therapeutically effective amount of amantadine, In one embodiment, the combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, is not administered with any amount of amantadine.

[0050] The (+)-α-dihydrotetrabenazine and / or (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, may be administered as an immediate release unit dosage form.

[0051] In another aspect, the present invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for use in medicine.

[0052] (+)-α-Dihydrotetrabenazine is believed to have the chemical structure (I) shown below: [ka]

[0053] (-)-α-Dihydrotetrabenazine is believed to have the chemical structure (II) shown below: [ka]

[0054] In another aspect, the present invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for use in medicine.

[0055] In a further aspect, the present invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof (in a pharmaceutical unit dosage form as defined above), for use in the treatment of a movement disorder.

[0056] In a further embodiment, the present invention provides: A method for treating a movement disorder in a subject (e.g., a mammalian subject, such as a human) in need of such treatment, comprising administering to the subject a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof.

[0057] Use of a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a movement disorder.

[0058] The inventors have also found that low doses of (+)-α-dihydrotetrabenazine (i.e. 20 mg or less per day) may be useful in the treatment of movement disorders and it is therefore believed that such low doses of (+)-α-dihydrotetrabenazine, in combination with (-)-α-dihydrotetrabenazine, are also useful in the treatment of movement disorders.

[0059] Thus, in another embodiment, the invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, for use in a method of treating a movement disorder, which method of treatment comprises administering to a subject (e.g. a human subject) in need thereof an effective therapeutic amount of the combination sufficient to provide a dosage of (+)-α-dihydrotetrabenazine of from 1 mg to 20 mg per day.

[0060] In a further aspect, the present invention provides: A method for treating a movement disorder, comprising administering to a subject (e.g., a human subject) in need thereof an effective therapeutic amount of a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, sufficient to provide a dose of 1 mg to 20 mg of (+)-α-dihydrotetrabenazine per day.

[0061] Use of a combination of (+)-alpha-dihydrotetrabenazine and (-)-alpha-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of a movement disorder, which method comprises administering to a subject (e.g. a human subject) in need thereof a therapeutically effective amount of the combination sufficient to provide a dosage of 1 mg to 20 mg of (+)-alpha-dihydrotetrabenazine per day.

[0062] Use of (-)-alpha-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for administration in combination with (+)-alpha-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for a method of treating a movement disorder, the method comprising administering to a subject (e.g. a human subject) in need thereof an effective therapeutic amount of the combination sufficient to provide a dosage of (+)-alpha-dihydrotetrabenazine of 1 mg to 20 mg per day.

[0063] In each of the foregoing embodiments (i.e., combinations, methods of use, or uses) using low doses of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof, the daily dose of (+)-α-dihydrotetrabenazine is from 1 mg to 20 mg.

[0064] In certain embodiments, the following are provided: A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 1.5 mg and 20 mg per day.

[0065] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 2 mg and 20 mg per day.

[0066] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 3 mg and 20 mg per day (e.g., between 3 mg and 20 mg).

[0067] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 2 mg and 15 mg per day (e.g., between 2 mg and 15 mg).

[0068] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 3 mg and 15 mg per day (e.g., between 3 mg and 15 mg).

[0069] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of (+)-alpha-dihydrotetrabenazine between 5 mg and 15 mg per day (e.g., between 5 mg and 15 mg).

[0070] Administration of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine typically forms part of a chronic treatment regimen. Thus, (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine may be administered to the patient for a treatment period of at least one week, more usually at least two weeks, or at least one month, typically longer than one month. If the patient is shown to respond well to the treatment, the treatment period may be longer than six months and may extend over several years.

[0071] A chronic treatment regimen may involve daily administration of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or the treatment regimen may include days when neither (+)-α-dihydrotetrabenazine nor (-)-α-dihydrotetrabenazine is administered.

[0072] The dosage administered to the subject may vary during the treatment period. For example, the initial dosage may be increased or decreased depending on the subject's response to the treatment. For example, the subject may be given an initial low dose to test the subject's tolerance to (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, and then the dosage may be increased as needed up to a maximum daily intake of 20 mg. Alternatively, the initial daily dosage administered to the patient may be selected to provide a predicted desired degree of VMAT2 blockade, and then a lower maintenance dose may be given for the remainder of the treatment period, with the option of increasing the dosage if the subject's response to the treatment indicates that an increase is necessary.

[0073] It is envisaged that the amount of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine required to achieve the desired therapeutic effect will depend on the body weight of the subject being treated. The amount of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine administered to a subject can be expressed in mg / kg, where kg relates to the body weight of the subject being treated. Thus, the appropriate dose can be calculated by multiplying the mg / kg amount by the body weight of the subject being treated.

[0074] Accordingly, in another aspect, the present invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine or pharma- ceutically acceptable salts thereof, for use in a method for the treatment of a movement disorder, wherein the treatment comprises administering to a subject an amount of the combination between 0.01 mg / kg and 0.3 mg / kg (e.g. between 0.01 mg / kg and 0.3 mg / kg) per day, provided that the total amount of (+)-α-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0075] In a further aspect, the present invention provides: A method for treating a movement disorder in a subject (e.g., a mammalian subject such as a human) in need thereof, comprising administering to the subject a combination of (+)-alpha-dihydrotetrabenazine and (-)-alpha-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, in an amount of 0.01 mg / kg to 0.3 mg / kg (e.g., between 0.01 mg / kg and 0.3 mg / kg) per day, provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0076] Use of a combination of (+)-alpha-dihydrotetrabenazine and (-)-alpha-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a movement disorder, which comprises administering to a subject the combination in an amount of 0.01 mg / kg to 0.3 mg / kg (e.g. between 0.01 mg / kg and 0.3 mg / kg), provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0077] In each of the foregoing embodiments (i.e. combinations, methods of use or uses) in which the combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, is administered in an amount of 0.01 mg / kg to 0.3 mg / kg (e.g., between 0.01 mg / kg and 0.3 mg / kg) per day, the daily dose of (+)-α-dihydrotetrabenazine is 1 mg to 20 mg.

[0078] In certain embodiments, the following is provided: A combination, method or use for use as described herein, wherein treatment comprises administering to a subject an amount of the combination of 0.02 mg / kg to 0.3 mg / kg (e.g. between 0.02 mg / kg and 0.3 mg / kg) per day, provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0079] A combination, method or use for use as described herein, wherein treatment comprises administering to a subject an amount of the combination of 0.03 mg / kg to 0.3 mg / kg (e.g. between 0.03 mg / kg and 0.3 mg / kg) per day, provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0080] A combination, method or use for use as described herein, wherein treatment comprises administering to a subject an amount of the combination of 0.04 mg / kg to 0.3 mg / kg (e.g. between 0.04 mg / kg and 0.3 mg / kg) per day, provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0081] A combination, method or use for use as described herein, wherein treatment comprises administering to a subject an amount of the combination of (+)-alpha-dihydrotetrabenazine of 0.05 mg / kg to 0.3 mg / kg (e.g. between 0.05 mg / kg and 0.3 mg / kg), provided that the total amount of (+)-alpha-dihydrotetrabenazine administered per day is in the range of 1 mg to 20 mg.

[0082] The combinations of the invention (and dosage forms containing the combinations) are useful in the treatment of movement disorders, in particular hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

[0083] More particularly, the combinations of the invention (and dosage forms containing the combinations) are for use in the treatment of a hyperkinetic movement disorder selected from tic disorders, Huntington's disease, tardive dyskinesia and Tourette's syndrome.

[0084] In one particular embodiment, the combination of the invention (and dosage forms comprising this combination) is for use in the treatment of tardive dyskinesia.

[0085] In another specific embodiment, the combination of the invention (and dosage forms comprising said combination) is for use in the treatment of Tourette's syndrome.

[0086] The utility of the combination of the present invention in the treatment of movement disorders arises in part from the ability of (+)-α-dihydrotetrabenazine to bind to the vesicular monoamine transporter 2 (VMAT2).

[0087] Complete blockade of the VMAT2 protein is considered undesirable as it may result in undesirable side effects (e.g., Parkinsonism). The present invention provides plasma levels of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine that are sufficient to provide effective treatment of movement disorders, but do not block the VMAT2 protein to an extent that causes Parkinsonism and similar side effects. The level of VMAT2 blockade can be determined by competitive binding studies using positron emission tomography (PET). By co-administering a radioligand with the compound of interest at various concentrations, the percentage of binding sites that are occupied can be determined (see, e.g., Matthews et al., "Positron emission tomography molecular imaging for drug development", Br. J. Clin. Pharmacol, 73:2, 175-186).

[0088] Accordingly, in a further aspect, the present invention provides a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, for use in a method for the treatment of a movement disorder, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a level of VMAT2 protein blockade in the subject of between 20% and 90%.

[0089] In a further aspect, the present invention provides: A method of treating a movement disorder in a subject (e.g., a mammalian subject such as a human) in need thereof, comprising administering to the subject a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or pharma- ceutically acceptable salts thereof, sufficient to cause a 20%-90% blockade level of VMAT2 protein in the subject.

[0090] Use of a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a movement disorder in a subject (e.g., a mammalian subject such as a human), which treatment comprises administering to the subject an amount of the combination sufficient to cause a level of VMAT2 protein blockade in the subject of between 20% and 90%.

[0091] (+)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, in combination with (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of a movement disorder in a subject (e.g. a mammalian subject, such as a human), which treatment comprises administering to the subject an amount of the combination sufficient to cause a level of VMAT2 protein blockade of 20% to 90% in the subject.

[0092] In a further embodiment, the following is provided: A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a blocking level of 25%-85% of VMAT2 protein in the subject.

[0093] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 30%-85% blocking level of VMAT2 protein in the subject.

[0094] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 35%-85% blocking level of VMAT2 protein in the subject.

[0095] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 40%-85% blocking level of VMAT2 protein in the subject.

[0096] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 45%-85% blocking level of VMAT2 protein in the subject.

[0097] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 50%-85% blocking level of VMAT2 protein in the subject.

[0098] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 30%-80% blocking level of VMAT2 protein in the subject.

[0099] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 35%-75% blocking level of VMAT2 protein in the subject.

[0100] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 35%-70% blocking level of VMAT2 protein in the subject.

[0101] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 40%-75% blocking level of VMAT2 protein in the subject.

[0102] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to cause a 45%-75% blocking level of VMAT2 protein in the subject.

[0103] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to cause a 35%-80% blocking level of VMAT2 protein in the subject.

[0104] A combination, method or use for use as described herein, wherein treatment comprises administering to a subject in need thereof, and wherein the method comprises administering to the subject an amount of the combination sufficient to cause a 40%-80% blocking level of VMAT2 protein in the subject.

[0105] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 45%-80% blocking level of VMAT2 protein in the subject.

[0106] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 50%-80% blocking level of VMAT2 protein in the subject.

[0107] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a 55%-80% blocking level of VMAT2 protein in the subject.

[0108] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject an amount of the combination sufficient to cause a blockade level of VMAT2 protein of 30%-70% (e.g., between 30% and 70%) in the subject.

[0109] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 30%-65% (e.g., between 30% and 65%).

[0110] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 30%-60% (e.g., between 30% and 60%).

[0111] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 40%-80% (e.g., between 40% and 80%).

[0112] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 40%-75% (e.g., between 40% and 75%).

[0113] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 40%-70% (e.g., between 40% and 70%).

[0114] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 40%-65% (e.g., between 40% and 65%).

[0115] A combination, method or use for use as described herein, wherein the treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of the combination sufficient to achieve a blockade level of VMAT2 protein in the subject of 40%-60% (e.g., between 40% and 60%).

[0116] In each of the foregoing aspects and embodiments of the invention, the combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine may be racemic.

[0117] Alternatively, in each of the foregoing aspects and embodiments of the invention, the combination of (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine may be scalemic (ie non-racemic).

[0118] In each of the combinations of the present invention, the use thereof, and pharmaceutical dosage forms containing the combination as defined above, the ratio of (+)-α-dihydrotetrabenazine to (-)-α-dihydrotetrabenazine in the combination may be, for example, from 0.5:1 to 20:1. In certain embodiments, the ratio of (+)-α-dihydrotetrabenazine to (-)-α-dihydrotetrabenazine in the combination may be in a ratio range selected from the following:

[0119] (i) 1:1~20:1 (ii) 1:1 to 15:1 (iii) 1:1 to 12:1 (iv) 1:1 to 10:1 (v) 1:1~5:1 (vi) 1:1~4:1 (vii) 1:1~3:1 (viii) 1:1~2:1

[0120] (ix) 1.1:1 to 20:1 (x) 1.1:1~15:1 (xi) 1.1:1 to 12:1 (xii) 1.1:1 to 10:1 (xiii) 1.1:1 to 5:1 (xiv) 1.1:1 to 4:1 (xv) 1.1:1~3:1 (xvi) 1.1:1~2:1 (xvii) 1.2:1~20:1 (xviii) 1.2:1 to 15:1 (xix) 1.2:1~12:1 (xx) 1.2:1~10:1 (xxi) 1.2:1~5:1 (xxii) 1.2:1~4:1 (xxiii) 1.2:1~3:1 (xxiv) 1.2:1~2:1

[0121] In each of the foregoing aspects and embodiments of the invention, the combination of (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine is typically not accompanied by other dihydrotetrabenazine isomers.

[0122] Although small amounts of other tetrabenazine isomers may be present in some embodiments, they will generally be present in an amount corresponding to 20% or less by weight (i.e., 0.2:1) relative to the total weight of the combination. More usually, the other dihydrotetrabenazine isomers will be present in an amount corresponding to 10% or less by weight, 5% or less by weight, or 2% or less by weight, or 1% or less by weight (i.e., 0.2:1) relative to the total weight of the combination. More preferably, the other dihydrotetrabenazine isomers will be completely absent or present in an amount less than 1% by weight, for example less than 0.5% by weight.

[0123] In each of the foregoing aspects and embodiments, (+)-α-dihydrotetrabenazine and / or (-)-α-dihydrotetrabenazine may be administered as the free base or as a pharma- ceutically acceptable salt. In one embodiment, one or both of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine are administered as a pharma- ceutically acceptable salt. In another embodiment, both (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine are administered as the free base. Unless otherwise stated or the context dictates otherwise, the amounts of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine are calculated as the amount of the free base or, if (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine is in the form of a pharma-ceutically acceptable salt, the amount of (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine itself present in the pharma-ceutically acceptable salt.

[0124] In each of the foregoing aspects and embodiments of the invention relating to combinations of (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof, typically the (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof is not administered with a therapeutically effective amount of amantadine, more particularly the (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof is not administered with any amount of amantadine.

[0125] For example, with respect to pharmaceutical unit dosage forms, typically the unit dosage form does not contain a therapeutically effective amount of amantadine, and more particularly the pharmaceutical unit dosage form does not contain any amount of amantadine.

[0126] Furthermore, in each of the foregoing aspects and embodiments of the invention relating to (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or a pharma-ceutically acceptable salt thereof, the pharmaceutical unit dosage form may be other than a sustained or delayed release dosage form.

[0127] Thus, for example, (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, may be administered as an immediate release unit dosage form.

[0128] (+)-β-Dihydrotetrabenazine As discussed above, the inventors have found that (+)-α-dihydrotetrabenazine does not appear to be a major contributor to the therapeutic properties of tetrabenazine. Conversely, (+)-α-dihydrotetrabenazine appears to make only a relatively minor contribution to the therapeutic properties of tetrabenazine.

[0129] Thus, despite previous findings that the (+)-α-isomer was 3-4 times more active than the (+)-β-isomer, the fact that the (+)-β-isomer was present in the body in >50-fold greater amounts following administration of tetrabenazine suggests that (+)-β-dihydrotetrabenazine is the primary contributor to tetrabenazine's activity.

[0130] According to the inventors' research, (+)-β-dihydrotetrabenazine itself has the chemical name (S,R,R)-3-isobutyl-9,10-dimethyloxy-1,3,4,5,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol and the following formula (III): [ka] However, despite previous findings that it has lower VMAT2 activity than (+)-α-dihydrotetrabenazine, it is effective in treating movement disorders.

[0131] Thus, in a first aspect, the present invention provides a unit dosage form comprising (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0132] In another aspect, the present invention provides (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, for use in medicine.

[0133] Also provided is a unit dosage form comprising (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient that is substantially free of other dihydrotetrabenazine isomers.

[0134] The unit dosage form may be one that is administered orally, for example a capsule or tablet, or the (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof may be administered in a non-solid dosage form, such as an aqueous solution, syrup, suspension or gel.

[0135] In certain embodiments of the present invention, there is provided: A unit dosage form comprising 1 mg to 200 mg (e.g., between 1 mg and 200 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0136] A unit dosage form comprising 1 mg to 150 mg (e.g., between 1 mg and 150 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0137] A unit dosage form comprising 1 mg to 100 mg (e.g., between 1 mg and 100 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0138] A unit dosage form comprising 1 mg to 80 mg (e.g., between 1 mg and 80 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0139] A unit dosage form comprising 3 mg to 200 mg (e.g., between 3 mg and 200 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0140] A unit dosage form comprising 3 mg to 150 mg (e.g., between 3 mg and 150 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0141] A unit dosage form comprising 3 mg to 100 mg (e.g., between 3 mg and 100 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0142] A unit dosage form comprising 3 mg to 80 mg (e.g., between 3 mg and 80 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0143] A unit dosage form comprising 5 mg to 200 mg (e.g., between 5 mg and 200 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0144] A unit dosage form comprising 5 mg to 150 mg (e.g., between 5 mg and 150 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0145] A unit dosage form comprising 5 mg to 100 mg (e.g., between 5 mg and 100 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0146] A unit dosage form comprising 5 mg to 80 mg (e.g., between 5 mg and 80 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0147] A unit dosage form comprising 3 mg to 60 mg (e.g., between 3 mg and 60 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0148] A unit dosage form comprising 5 mg to 60 mg (e.g., between 5 mg and 60 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0149] A unit dosage form comprising 10 mg to 60 mg (e.g., between 10 mg and 60 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0150] A unit dosage form comprising 15 mg to 60 mg (e.g., between 15 mg and 60 mg) of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0151] A unit dosage form comprising approximately 20 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0152] A unit dosage form comprising approximately 30 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0153] A unit dosage form comprising approximately 40 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0154] A unit dosage form comprising approximately 50 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0155] A unit dosage form comprising approximately 60 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

[0156] The unit dosage forms as defined and described above are typically for use in the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

[0157] More particularly, said unit dosage form is for use in the treatment of a hyperkinetic movement disorder selected from tic disorders, Huntington's disease, tardive dyskinesia and Tourette's syndrome.

[0158] In one particular embodiment, the unit dosage form is for use in the treatment of tardive dyskinesia.

[0159] In another specific embodiment, the unit dosage form is for use in treating Tourette's syndrome.

[0160] The present inventors have found that (+)-β-dihydrotetrabenazine is useful for blocking VMAT2 receptors in the treatment of movement disorders.Accordingly, the present invention provides a pharmaceutical composition comprising (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.

[0161] The present invention also provides (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for use as a VMAT2 inhibitor.

[0162] In further embodiments of the present invention, there is provided: (+)-β-Dihydrotetrabenazine or a pharma- ceutical acceptable salt thereof for use in the treatment of hyperkinetic movement disorder.

[0163] (+)-β-Dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for use in the treatment of Huntington's disease, hemiballismus, geriatric chorea, tic disorders, tardive dyskinesia, dystonia or Tourette's syndrome.

[0164] A method for treating hyperkinetic movement disorder in a subject (e.g., a mammalian subject, such as a human) in need thereof, comprising administering to the subject a therapeutically effective amount of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0165] A method for treating Huntington's disease, hemiballismus, senile chorea, tic disorder, tardive dyskinesia, dystonia or Tourette's syndrome in a subject in need of such treatment (e.g. a mammalian subject such as a human), comprising administering to the subject a therapeutically effective amount of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0166] Use of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for the treatment of hyperkinetic movement disorder.

[0167] Use of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia or Tourette's syndrome.

[0168] (+)-beta-dihydrotetrabenazine for use in a method for the treatment of a movement disorder, the treatment comprising administering to a subject the (+)-beta-dihydrotetrabenazine in an amount between 1 mg and 200 mg (e.g. between 1 mg and 200 mg) per day.

[0169] A method of treating a movement disorder in a subject (e.g., a mammalian subject such as a human) in need thereof, comprising administering to the subject (+)-β-dihydrotetrabenazine in an amount of 1 mg to 200 mg (e.g., between 1 mg and 200 mg) per day.

[0170] Use of (+)-β-dihydrotetrabenazine for the manufacture of a medicament for the treatment of a movement disorder, wherein the treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 1 mg and 200 mg per day (e.g., between 1 mg and 200 mg).

[0171] Typically, (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, is not administered with an effective amount of amantadine. In one embodiment, (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, is not administered with amantadine.

[0172] The (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, may be administered as an immediate release unit dosage form.

[0173] In a further embodiment, the following is provided: (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount between 1 mg and 150 mg (e.g. between 1 mg and 150 mg) per day.

[0174] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount between 1 mg and 100 mg (e.g. between 1 mg and 100 mg) per day.

[0175] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount between 1 mg and 80 mg (e.g. between 1 mg and 80 mg) per day.

[0176] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 3 mg and 200 mg per day.

[0177] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 3 mg and 150 mg per day (e.g., between 3 mg and 150 mg).

[0178] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 3 mg and 100 mg per day.

[0179] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 5 mg and 200 mg per day (e.g. between 5 mg and 200 mg).

[0180] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 5 mg and 150 mg (e.g. between 5 mg and 150 mg) per day.

[0181] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 5 mg and 100 mg (e.g. between 5 mg and 100 mg) per day.

[0182] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 1 mg and 70 mg per day (e.g., between 1 mg and 70 mg).

[0183] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount between 1 mg and 60 mg (e.g. between 1 mg and 60 mg) per day.

[0184] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount between 1 mg and 50 mg (e.g. between 1 mg and 50 mg) per day.

[0185] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 5 mg and 70 mg per day (e.g., between 5 mg and 70 mg).

[0186] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine between 5 mg and 60 mg per day (e.g., between 5 mg and 60 mg).

[0187] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount of about 10 mg per day.

[0188] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount of about 15 mg per day.

[0189] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount of about 20 mg per day.

[0190] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount of about 30 mg per day.

[0191] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject (+)-β-dihydrotetrabenazine in an amount of about 40 mg per day.

[0192] In each case, the amount of (+)-β-dihydrotetrabenazine specified may be administered in a single dose per day, or in several (eg, two) doses per day.

[0193] In some embodiments, the amount of (+)-β-dihydrotetrabenazine specified is administered once a day.

[0194] Administration of (+)-β-dihydrotetrabenazine typically forms part of a chronic treatment regimen. Thus, (+)-β-dihydrotetrabenazine may be administered to the patient for a treatment period of at least one week, more usually at least two weeks, or at least one month, typically longer than one month. If the patient is shown to respond well to the treatment, the treatment period may be longer than six months and may extend over several years.

[0195] A chronic treatment regimen may involve daily administration of (+)-β-dihydrotetrabenazine or the treatment regimen may include days when (+)-β-dihydrotetrabenazine is not administered.

[0196] The dosage administered to the subject may vary during the treatment period. For example, the initial dosage may be increased or decreased depending on the subject's response to the treatment. For example, the subject may be given an initial low dose to test the subject's tolerance to (+)-β-dihydrotetrabenazine, and then the dosage may be increased, if necessary, to a maximum daily intake of 80 mg (or other daily intake as described above). Alternatively, the initial daily dosage administered to the patient may be selected to provide a predicted desired degree of VMAT2 blockade, and then a lower maintenance dose may be given for the remainder of the treatment period, with the option of increasing the dosage if the subject's response to the treatment indicates that an increase is necessary.

[0197] The amount of (+)-β-dihydrotetrabenazine required to achieve a desired therapeutic effect may depend on the body weight of the subject being treated. The amount of (+)-β-dihydrotetrabenazine administered to a subject may be defined as the weight in milligrams of (+)-β-dihydrotetrabenazine administered to a subject per kilogram of the subject's body weight, which may be abbreviated as mg / kg. Thus, the appropriate dosage may be calculated by multiplying the mg / kg amount by the body weight of the subject being treated. Thus, the present invention also provides:

[0198] (+)-beta-dihydrotetrabenazine for use in a method for the treatment of a movement disorder, the treatment comprising the step of administering to a subject (+)-beta-dihydrotetrabenazine in an amount between 0.01 mg / kg and 2.0 mg / kg (e.g. between 0.01 mg / kg and 2.0 mg / kg) per day, wherein the total amount of (+)-beta-dihydrotetrabenazine administered per day is in the range of 1 mg to 80 mg (or other range as defined above).

[0199] A method for treating a movement disorder in a subject (e.g., a mammalian subject such as a human) in need thereof, comprising administering to the subject (+)-β-dihydrotetrabenazine in an amount of 0.01 mg / kg to 2.0 mg / kg per day (e.g., between 0.01 mg / kg and 2.0 mg / kg), provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 80 mg (or other range as defined above).

[0200] Use of (+)-beta-dihydrotetrabenazine for the manufacture of a medicament for the treatment of a movement disorder, comprising administering to a subject an amount of (+)-beta-dihydrotetrabenazine between 0.01 mg / kg and 2.0 mg / kg per day (e.g. between 0.01 mg / kg and 2.0 mg / kg), provided that the total amount of (+)-beta-dihydrotetrabenazine administered per day is between 1 mg and 80 mg (or other range as defined above).

[0201] In a further embodiment, the following is provided: (+)-β-dihydrotetrabenazine for use as described herein, methods or uses, wherein treatment comprises administering to a subject 0.01 mg / kg to 1.5 mg / kg (e.g. between 0.01 mg / kg and 1.5 mg / kg) of (+)-β-dihydrotetrabenazine per day, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 80 mg (or other range as defined above).

[0202] (+)-β-dihydrotetrabenazine for use as described herein, the method or use comprising administering to a subject 0.1 mg / kg to 1.5 mg / kg (e.g. between 0.1 mg / kg and 1.5 mg / kg) of (+)-β-dihydrotetrabenazine, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 80 mg (or other range as defined above).

[0203] (+)-β-dihydrotetrabenazine for use as described herein, the method or use comprising administering to a subject 0.25 mg / kg to 1.5 mg / kg (e.g. between 0.25 mg / kg and 1.5 mg / kg) of (+)-β-dihydrotetrabenazine, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 80 mg (or other range as defined above).

[0204] (+)-β-dihydrotetrabenazine for use as described herein, the method or use comprising administering to a subject 0.01 mg / kg to 1.25 mg / kg (e.g. between 0.01 mg / kg and 1.25 mg / kg) of (+)-β-dihydrotetrabenazine per day, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 60 mg (or other range as defined above).

[0205] (+)-β-dihydrotetrabenazine for use as described herein, the method or use comprising administering to a subject 0.1 mg / kg to 1.25 mg / kg (e.g. between 0.1 mg / kg and 1.25 mg / kg) of (+)-β-dihydrotetrabenazine, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 60 mg (or other range as defined above).

[0206] (+)-β-dihydrotetrabenazine for use as described herein, the method or use comprising administering to a subject 0.25 mg / kg to 1.25 mg / kg (e.g. between 0.25 mg / kg and 1.25 mg / kg) of (+)-β-dihydrotetrabenazine, provided that the total amount of (+)-β-dihydrotetrabenazine administered per day is 1 mg to 60 mg (or other range as defined above).

[0207] In each of the foregoing aspects and embodiments, (+)-β-dihydrotetrabenazine may be administered as the free base or as a pharma- ceutically acceptable salt. Unless the context dictates otherwise, references herein to (+)-β-dihydrotetrabenazine also include pharma- ceutically acceptable salts thereof.

[0208] In one common embodiment, (+)-β-dihydrotetrabenazine is administered as a pharma- ceutically acceptable salt.

[0209] In another general embodiment, (+)-β-dihydrotetrabenazine is administered as the free base.

[0210] When amounts or ranges of amounts of (+)-β-dihydrotetrabenazine are recited herein, they are calculated as the amount of free base or, if the (+)-β-dihydrotetrabenazine is in the form of a pharma- ceutically acceptable salt, as the amount of (+)-β-dihydrotetrabenazine free base present in the pharma- ceutically acceptable salt.

[0211] Complete blockade of the VMAT2 protein is considered undesirable as it may cause undesirable side effects such as parkinsonism. The present invention provides plasma levels of (+)-β-dihydrotetrabenazine sufficient to provide effective treatment of movement disorders, but which do not block the VMAT2 protein to an extent that causes parkinsonism and similar side effects. The level of VMAT2 blockade can be determined by competitive binding studies using positron emission tomography (PET). By co-administering a radioligand with the compound of interest at various concentrations, the percentage of binding sites occupied can be determined (see, e.g., Matthews et al., "Positron emission tomography molecular imaging for drug development", Br. J. Clin. Pharmacol, 73:2, 175-186). Thus, the present invention also provides:

[0212] (+)-beta-dihydrotetrabenazine for use in a method for the treatment of a movement disorder, the treatment comprising administering to a subject an amount of (+)-beta-dihydrotetrabenazine sufficient to cause a level of VMAT2 protein blockade of up to 90% in the subject.

[0213] A method for treating a movement disorder in a subject (e.g., a mammalian subject such as a human) in need thereof, comprising administering to the subject (+)-β-dihydrotetrabenazine in an amount sufficient to cause a blockade level of VMAT2 protein of up to 90% in the subject.

[0214] Use of (+)-β-dihydrotetrabenazine for the manufacture of a medicament for the treatment of a movement disorder, wherein the treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of up to 90% in the subject.

[0215] In a further embodiment, the following is provided: (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of up to 85% in the subject.

[0216] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of up to 80% in the subject.

[0217] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of up to 75% in the subject.

[0218] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of up to 70% in the subject.

[0219] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 20% and 90% in the subject.

[0220] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 25% and 85% in the subject.

[0221] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 30% and 80% in the subject.

[0222] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 35% and 75% in the subject.

[0223] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a level of VMAT2 protein blockade of between 35% and 70% in the subject.

[0224] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 40% and 75% in the subject.

[0225] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 45% and 75% in the subject.

[0226] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 35% and 80% in the subject.

[0227] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 40% and 80% in the subject.

[0228] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 45% and 80% in the subject.

[0229] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 50% and 80% in the subject.

[0230] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of between 55% and 80% in the subject.

[0231] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 30% to 70% (e.g., between 30% and 70%) in the subject.

[0232] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 30% to 65% (e.g. between 30% and 65%) in the subject.

[0233] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 30% to 60% (e.g. between 30% and 60%) in the subject.

[0234] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 40% to 80% (e.g. between 40% and 80%) in the subject.

[0235] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 40% to 75% (e.g. between 40% and 75%) in the subject.

[0236] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 40% to 70% (e.g. between 40% and 70%) in the subject.

[0237] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 40% to 65% (e.g. between 40% and 65%) in the subject.

[0238] (+)-β-dihydrotetrabenazine for use as described herein, the method or use, wherein treatment comprises administering to a subject in need thereof, and the method comprises administering to the subject an amount of (+)-β-dihydrotetrabenazine sufficient to cause a blockade level of VMAT2 protein of 40% to 60% (e.g. between 40% and 60%) in the subject.

[0239] The movement disorder may be a hyperkinetic movement disorder such as Huntington's disease, hemiballismus, senile chorea, tic disorder, tardive dyskinesia, dystonia, myoclonus, and Tourette's syndrome. In one embodiment, the movement disorder is Tourette's syndrome.

[0240] In each of the foregoing embodiments, the (+)-β-dihydrotetrabenazine is accompanied by no more than 20% by weight, relative to the (+)-β-dihydrotetrabenazine, of any other isomer of dihydrotetrabenazine.

[0241] More usually, the (+)-β-dihydrotetrabenazine is associated with not more than 10% by weight of any other isomers of dihydrotetrabenazine relative to the (+)-β-dihydrotetrabenazine; preferably, not more than 5% by weight of any other isomers of dihydrotetrabenazine relative to the (+)-β-dihydrotetrabenazine; more preferably, not more than 2% by weight of any other isomers of dihydrotetrabenazine relative to the (+)-β-dihydrotetrabenazine. Most preferably, the (+)-β-dihydrotetrabenazine is associated with less than 1% (e.g. less than 0.5% or less than 0.1%) of any other isomers of dihydrotetrabenazine relative to the (+)-β-dihydrotetrabenazine.

[0242] Thus, (+)-β-dihydrotetrabenazine typically has an isomeric purity of at least 80%.

[0243] The term "isomeric purity" in this context refers to the amount of (+)-β-dihydrotetrabenazine present relative to the total amount or concentration of all isomeric forms of dihydrotetrabenazine. For example, if 90% of the total dihydrotetrabenazine present in a composition is (+)-β-dihydrotetrabenazine, then the isomeric purity is 90%.

[0244] The (+)-β-dihydrotetrabenazine of the present invention may have an isomeric purity of greater than 82%, greater than 85%, greater than 87%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.5%, or greater than 99.9%.

[0245] In each of the foregoing aspects and embodiments of the invention relating to (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof, typically the (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof is not administered with a therapeutically effective amount of amantadine, more particularly the (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof is not administered with any amount of amantadine.

[0246] For example, with respect to pharmaceutical unit dosage forms, typically the unit dosage form does not contain a therapeutically effective amount of amantadine, and more particularly the pharmaceutical unit dosage form does not contain any amount of amantadine.

[0247] Furthermore, in each of the foregoing aspects and embodiments of the invention relating to (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof, the pharmaceutical unit dosage form may be other than a sustained or delayed release dosage form.

[0248] Thus, for example, (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, may be administered as an immediate release unit dosage form.

[0249] Combinations of (+)-β-dihydrotetrabenazine with (-)-α-dihydrotetrabenazine and / or (+)-α-dihydrotetrabenazine In a further embodiment, (+)-β-dihydrotetrabenazine having the formula (III) [ka] and (-)-α-Dihydrotetrabenazine having the formula (II) [ka] and / or (+)-α-dihydrotetrabenazine having the formula (I) [ka] It is believed that such combinations will be useful, inter alia, in the prevention or treatment of disease states and conditions for which tetrabenazine is currently used or proposed. Thus, by way of example and not limitation, it is believed that these combinations of dihydrotetrabenazine isomers may be used in the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia, and especially Tourette's syndrome.

[0250] Thus, in a first aspect, the present invention provides a pharmaceutical combination comprising: (a) (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof; and One or both of the following: (b) (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and (c) (+)-α-Dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof.

[0251] In one embodiment, the present invention provides a pharmaceutical combination comprising: (a) (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof; and (b) (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0252] In another embodiment, the present invention provides a pharmaceutical combination comprising: (a) (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof; and (c) (+)-α-Dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof.

[0253] In another embodiment, the present invention provides a pharmaceutical composition comprising: (a) (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof; (b) (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and (c) (+)-α-Dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof.

[0254] (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine may be collectively referred to herein as "dihydrotetrabenazine isomers of the invention" or "isomers of dihydrotetrabenazine" or "dihydrotetrabenazine", unless the context dictates otherwise. When describing types of pharmaceutical formulations, they may also be collectively referred to as "active compounds".

[0255] The pharmaceutical combination may be substantially free of (-)-β-dihydrotetrabenazine. Thus, the present invention also provides a pharmaceutical combination as described herein, wherein the unit dosage form is substantially free of (-)-β-dihydrotetrabenazine.

[0256] By "substantially free of (-)-beta-dihydrotetrabenazine" is meant that the percentage by weight of (-)-beta-dihydrotetrabenazine present compared to the total weight of all isomers of dihydrotetrabenazine is less than 5%, preferably less than 3%, more preferably less than 2%, and most preferably less than 1%.

[0257] The relative proportions of (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine can be expressed in terms of parts by weight of each isomer. Thus, for example, a unit dosage form may contain from 35 to 75 parts by weight of (+)-β-dihydrotetrabenazine and 25 to 55 parts by weight of α-dihydrotetrabenazine (which may be either (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or a mixture thereof). It will be appreciated that the proportions expressed above as parts by weight can instead be expressed as molar ratios (since all isomers have the same molecular weight) in which case the relative proportions of the isomers can be expressed as a molar ratio of (+)-β-dihydrotetrabenazine:α-dihydrotetrabenazine (which may be either (+)-α-dihydrotetrabenazine or (-)-α-dihydrotetrabenazine or mixtures thereof) of 35-70:25-55.

[0258] In one embodiment, the pharmaceutical combination of the present invention comprises: (a) 40 to 65 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof (c) 40 to 65 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0259] For example, the pharmaceutical combination may include: (a) 45 to 55 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof (c) 45 to 55 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0260] In one particular embodiment, the pharmaceutical combination comprises (+)-β-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine in approximately equimolar amounts.

[0261] In another embodiment, the pharmaceutical combination of the present invention comprises: (a) 45 to 65 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; (b) 30 to 50 parts by weight of (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and optionally (c) 0.1 to 5 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0262] In another embodiment, the pharmaceutical combination of the present invention comprises: (a) 45 to 65 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; (b) 30 to 50 parts by weight of (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and optionally (c) 0.1 to 3 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0263] In another embodiment, the pharmaceutical combination of the present invention comprises: (a) 45 to 65 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; (b) 30 to 50 parts by weight of (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and optionally (c) 0.1 to 2 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0264] In a further embodiment, the pharmaceutical combination of the present invention comprises: (a) 45 to 65 parts by weight of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; (b) 30 to 50 parts by weight of (-)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof; and optionally (c) 0.1 to 1.5 parts by weight of (+)-α-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof.

[0265] Pharmaceutical combination means a combination of three dihydrotetrabenazines (a) and (b) and / or (c) in a form suitable for administration to a subject, typically a human or other animal subject. The term therefore excludes crude reaction mixtures, partially purified reaction products, whole blood samples, or blood fraction samples such as plasma, or other biological samples such as urine samples that contain the combination. It also excludes simple solutions of the combination in pharma- ceutical non-acceptable solvents (e.g., chloroform, dichloromethane) not normally used in pharmacology.

[0266] The pharmaceutical combination may be in the form of a mixture of pure compounds or the combination may include one or more pharma- ceutically acceptable excipients.

[0267] Typically, the pharmaceutical combination will be formulated as a unit dosage form containing pharma- ceutically acceptable excipients and a defined amount of dihydrotetrabenazine (a), (b) and / or (c).

[0268] In the pharmaceutical combination of the present invention, one or more of the three dihydrotetrabenazines (a), (b) and (c) may be formulated separately or may be used in combination, however more typically the three dihydrotetrabenazines (a), (b) and (c) are formulated together in a pharmaceutical composition, particularly a unit dosage form.

[0269] In unit dosage forms of the invention containing the combinations defined herein, the sum of the amounts of the three isomers (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine ("total amount") may be selected not to exceed 100 mg.

[0270] Typically, the pharmaceutical unit dosage form does not contain an effective amount of amantadine. In one embodiment, the pharmaceutical unit dosage form does not contain amantadine.

[0271] The pharmaceutical unit dosage form may be an immediate release unit dosage form.

[0272] In certain embodiments: The total amount of the three isomers does not exceed 75 mg, The total amount of the three isomers does not exceed 50 mg, The total amount of the three isomers does not exceed 40 mg, The total amount of the three isomers does not exceed 30 mg, The total amount of the three isomers does not exceed 20 mg.

[0273] The unit dosage form can be one that is administered orally, such as a capsule or tablet.

[0274] The unit dosage form can be one that is administered orally, such as a capsule or tablet.

[0275] The pharmaceutical combinations defined herein are provided for use in medicine.

[0276] More particularly, the pharmaceutical combinations (and unit dosage forms) as defined and described above are provided for use in the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

[0277] More particularly, the above pharmaceutical combination (and unit dosage form) is for use in the treatment of a hyperkinetic movement disorder selected from tic disorders, Huntington's disease, tardive dyskinesia and Tourette's syndrome.

[0278] In one particular embodiment, the above pharmaceutical combination (and unit dosage form) is for use in the treatment of tardive dyskinesia.

[0279] In another particular embodiment, the above pharmaceutical combination (and unit dosage form) is for use in the treatment of Tourette's syndrome.

[0280] In a further aspect, the present invention provides: A pharmaceutical combination as defined herein for use in the treatment of hyperkinetic movement disorders.

[0281] A method for treating hyperkinetic movement disorder in a subject (e.g. a mammalian subject such as a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination as defined herein.

[0282] - The use of a pharmaceutical combination as defined herein for the manufacture of a medicament for the treatment of hyperkinetic movement disorder.

[0283] The unit dosage form for use, the pharmaceutical combination for use, the method or the use as described herein, wherein the hyperkinetic movement disorder is selected from Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

[0284] The unit dosage form for use, the pharmaceutical combination for use, the method or the use as described herein, wherein the hyperkinetic movement disorder is Tourette's syndrome.

[0285] In each case, (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine; and optionally the combination of (+)-α-dihydrotetrabenazine are typically administered once daily.

[0286] Complete blockade of VMAT2 is considered undesirable as it may cause undesirable side effects such as parkinsonism. The present invention provides plasma levels of dihydrotetrabenazine sufficient to provide effective treatment of movement disorders, but which do not block VMAT2 to an extent that causes parkinsonism and similar side effects. The level of VMAT2 blockade can be determined by competitive binding studies using positron emission tomography (PET). By co-administering a radioligand with the compound of interest at various concentrations, the percentage of binding sites occupied can be determined (see, e.g., Matthews et al., "Positron emission tomography molecular imaging for drug development", Br. J. Clin. Pharmacol, 73:2, 175-186). Thus, the present invention also provides:

[0287] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of greater than 20% in the subject.

[0288] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of greater than 30% in the subject.

[0289] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of greater than 40% in the subject.

[0290] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of less than 90% in the subject.

[0291] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of less than 85% in the subject.

[0292] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of less than 80% in the subject.

[0293] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of less than 75% in the subject.

[0294] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of less than 70% in the subject.

[0295] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 20%-90% (e.g., between 20% and 90%) in the subject.

[0296] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 30%-80% (e.g., between 30% and 80%) in the subject.

[0297] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 30%-75% (e.g., between 30% and 75%) in the subject.

[0298] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 30%-70% (e.g., between 30% and 70%) in the subject.

[0299] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 30%-65% (e.g., between 30% and 65%) in the subject.

[0300] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 30%-60% (e.g., between 30% and 60%) in the subject.

[0301] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 40%-80% (e.g., between 40% and 80%) in the subject.

[0302] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 40%-75% (e.g., between 40% and 75%) in the subject.

[0303] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 40%-70% (e.g., between 40% and 70%) in the subject.

[0304] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 40%-65% (e.g., between 40% and 65%) in the subject.

[0305] A unit dosage form for use, pharmaceutical combination for use, method or use as described herein, wherein treatment comprises administering to a subject an amount of the unit dosage form or combination sufficient to cause a blockade level of VMAT2 protein of 40%-60% (e.g., between 40% and 60%) in the subject.

[0306] In each of the foregoing aspects and embodiments of the invention relating to combinations of dihydrotetrabenazine (a) and (b) and / or (c), typically the combination is not administered with a therapeutically effective amount of amantadine, more particularly, the combination is not administered with any amount of amantadine.

[0307] For example, with respect to pharmaceutical unit dosage forms, typically the unit dosage form does not contain a therapeutically effective amount of amantadine, and more particularly the pharmaceutical unit dosage form does not contain any amount of amantadine.

[0308] Furthermore, in each of the foregoing aspects and embodiments of the invention relating to combinations of dihydrotetrabenazines (a) and (b) and / or (c), the pharmaceutical unit dosage form may be other than a sustained or delayed release dosage form.

[0309] Thus, for example, the combination of dihydrotetrabenazine (a) and (b) and / or (c) may be administered as an immediate release unit dosage form.

[0310] Free bases and salts In each of the foregoing aspects and embodiments of the invention, all references herein to individual isomers of dihydrotetrabenazine refer to both the free base and salts thereof, unless the context dictates otherwise.

[0311] The salts are typically acid addition salts. The salts can be synthesized from the parent compound by conventional chemical methods such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (editor), Camille G. Wermuth (editor), ISBN: 3-90639-026-8, hardcover, 388 pages, August, 2002. In general, such salts can be prepared by reacting the free base form of the compound with an acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media such as ether, acetone, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.

[0312] Acid addition salts can be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butanoic acid, (+)camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-oxoglutaric acid, glycolic acid, hippuric acid, bromide, Included are salts formed with acids selected from the group consisting of hydrochloric acid, hydroiodic acid, isethionic acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and valeric acid, as well as acylated amino acids and cation exchange resins.

[0313] The salt forms of the compounds of the present invention are typically pharma- ceutically acceptable salts, and examples of pharma- ceutically acceptable salts are described in Berge et al., 1977, "Pharmaceutically Acceptable Salts", J.PharmSci., Vol. 66, pp. 1-19. However, pharma- ceutically unacceptable salts may also be prepared as intermediate forms, which may then be converted into pharma- ceutical acceptable salts. Such pharma- ceutical unacceptable salt forms may also be useful, for example, in the purification or separation of the compounds of the present invention, and form part of the present invention.

[0314] Isomers of dihydrotetrabenazine may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element. For example, a reference to hydrogen includes within its scope: 1 H, 2 H(D), and 3 Similarly, references to carbon and oxygen each include within their scope: 11 C. 12 C. 13 C and 14 C and 16 O and 18 Contains O.

[0315] Typically, an isomer of dihydrotetrabenazine of the present invention contains an isotope that is greater than its natural abundance (e.g., 11 C or 3 H) is not included.

[0316] In one embodiment, the percentage of total hydrogen atoms in (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine that are deuterium atoms is less than 2%, more typically less than 1%, more usually less than 0.1%, preferably less than 0.05%, and most preferably 0.02% or less.

[0317] In a similar manner, reference to a particular functional group also includes isotopic variations within its scope unless the context dictates otherwise.

[0318] The isotope may be radioactive or non-radioactive. In one embodiment of the present invention, the dihydrotetrabenazine isomer does not contain a radioisotope. Such compounds are preferred for therapeutic use. However, in another embodiment, one or more of the dihydrotetrabenazine isomers may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in diagnostic situations.

[0319] Reference to an isomer of dihydrotetrabenazine includes any solvates formed by the compound.

[0320] An example of a solvate is a solvate formed by incorporating a molecule of a non-toxic pharma- ceutically acceptable solvent (hereinafter referred to as a solvating solvent) into the solid-state structure (e.g., crystalline structure) of a compound of the present invention. Examples of such solvents include water, alcohol (e.g., ethanol, isopropanol, and butanol) and dimethylsulfoxide. A solvate can be prepared by recrystallizing a compound of the present invention using a solvent or a mixture of solvents containing a solvating solvent. Whether a solvate is formed in any given example can be determined by analyzing the crystal of the compound using well-known standard techniques such as thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and X-ray crystallography.

[0321] The solvates may be stoichiometric or non-stoichiometric solvates. Particular examples of solvates are hydrates, such as hemihydrates, monohydrates and dihydrates.

[0322] For a more detailed discussion of solvates and the methods used to make and characterize them, see Bryn et al., Solid-State Chemistry of Drugs, 2nd Edition, published by SSCI, Inc. of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.

[0323] Alternatively, rather than existing as a hydrate, the compounds of the invention may be anhydrous. Thus, in another embodiment, one or more of the isomers of dihydrotetrabenazine are in anhydrous form.

[0324] Process for the preparation of dihydrotetrabenazine isomers (+)-α-Dihydrotetrabenazine and (−)-α-dihydrotetrabenazine can be prepared from tetrabenazine according to the synthetic route shown in Scheme 1. [ka]

[0325] Racemic tetrabenazine (3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1,a]isoquinolin-2-one) containing the RR and SS isomers of tetrabenazine was reduced with sodium borohydride to give a mixture of four dihydrotetrabenazine isomers, with a racemic mixture of α-dihydrotetrabenazine (RRR and SSS isomers) constituting the major product and a racemic mixture of β-dihydrotetrabenazine (SRR and RSS isomers) constituting the by-product. The β-dihydrotetrabenazine can be removed during an initial purification procedure, for example by chromatography or recrystallization, and the racemic α-dihydrotetrabenazine can then be separated by well-known methods such as chiral chromatography or the formation of diastereomeric salts by reaction with a chiral acid followed by separation by recrystallization.

[0326] For example, (+)-α-dihydrotetrabenazine isomer (I) (((2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1,a]isoquinolin-2-ol) can be obtained by recrystallization of the racemic mixture with di-p-toluoyl-L-tartaric acid or (R)-(-)-camphorsulfonic acid or by chiral chromatography.

[0327] The (-)-α-dihydrotetrabenazine isomer (I) ((2S,3S,11bS)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1,a]isoquinolin-2-ol) can be obtained by recrystallization of the racemic mixture with di-p-toluoyl-R-tartaric acid or (L)-(+)-camphorsulfonic acid or by chiral chromatography.

[0328] (+)-α-Dihydrotetrabenazine and (-)-α-dihydrotetrabenazine may also be prepared according to Yao et al., "Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors", Eur. J. Med. Chem., (2011), 46, pp. 1841-1848.

[0329] (+)-β-Dihydrotetrabenazine (compound of formula (III)) can be prepared from tetrabenazine according to the synthetic route shown in Scheme 2. [ka]

[0330] Racemic tetrabenazine (3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1,a]isoquinolin-2-one) containing the RR and SS isomers of tetrabenazine was reduced with sodium borohydride to give a mixture of four dihydrotetrabenazine isomers of which a racemic mixture of β-dihydrotetrabenazine (SRR and RSS isomers) constituted the major product and a racemic mixture of α-dihydrotetrabenazine (RRR and SSS isomers) constituted the by-product. The α-dihydrotetrabenazine is removed during an initial purification procedure, for example by chromatography or recrystallization, and then the racemic β-dihydrotetrabenazine is resolved (for example by recrystallization with di-p-toluoyl-L-tartaric acid or (R)-(-)-camphorsulfonic acid, or by chiral chromatography) to give (+)-β-dihydrotetrabenazine (III) ((2S,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1,a]isoquinolin-2-ol). The stereochemical configuration of (+)-β-dihydrotetrabenazine can be determined, for example, by forming a salt, such as the mesylate salt, in crystalline form and identifying the structure by X-ray crystallography.

[0331] (+)-α-Dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and (+)-β-dihydrotetrabenazine may also be prepared according to Yao et al., “Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors”, Eur. J. Med. Chem., (2011), 46, pp. 1841-1848.

[0332] Once prepared and purified, (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and, where present, (+)-α-dihydrotetrabenazine, or their respective salts, may be mixed in the required proportions.

[0333] Pharmaceutical preparations and methods of treatment The pharmaceutical unit dosage forms of the present invention may be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, ophthalmic, otic, rectal, vaginal, or transdermal administration. If the compositions are intended for parenteral administration, they may be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration, or for direct delivery to a target organ or tissue by injection, infusion, or other delivery means.

[0334] Pharmaceutical unit dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, sprays, powders, granules, elixirs and suspensions, sublingual tablets, sprays, wafers or patches and buccal patches.

[0335] Particular examples of pharmaceutical unit dosage forms containing the combinations of the invention are capsules and tablets.

[0336] Pharmaceutical unit dosage forms containing the combinations of the invention can be formulated according to well-known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

[0337] Thus, the tablet composition may contain a unit dosage of the combination of active compounds together with an inert diluent or carrier, such as a sugar or sugar alcohol (e.g., lactose, sucrose, sorbitol or mannitol); and / or a non-sugar derived diluent (e.g., sodium carbonate, calcium phosphate, talc, calcium carbonate), or a cellulose or its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose), and starch (e.g., corn starch). Tablets may also contain standard ingredients such as binding agents and granulating agents, such as polyvinylpyrrolidone, disintegrants (e.g., swellable cross-linked polymers, such as cross-linked carboxymethylcellulose), lubricants (e.g., stearates), preservatives (e.g., parabens), antioxidants (e.g., BHT), buffers (e.g., phosphate or citrate buffers), and effervescent agents, such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail here.

[0338] Capsule formulations may be of the hard or soft gelatin variety and may contain the active ingredient in solid, semi-solid, or liquid form. Gelatin capsules may be formed from animal gelatin or its synthetic or vegetable derived equivalents.

[0339] Solid dosage forms (e.g., tablets, capsules, etc.) may be coated or uncoated, but typically have a coating, such as a protective film coating (e.g., wax or varnish) or a release-controlling coating. The coating (e.g., Eudragit™-type polymer) can be designed to release the active ingredient at a desired location in the gastrointestinal tract. Thus, the coating can be selected to degrade at specific pH conditions in the gastrointestinal tract, thereby selectively releasing the compound in the stomach or ileum or duodenum.

[0340] Alternatively, or in addition to a coating, the dihydrotetrabenazine isomers, or pharma- ceutically acceptable salts thereof, which constitute the combination of the invention may be presented in a solid matrix comprising a release controlling agent, e.g. a release retarding agent, which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract. Alternatively, the matrix material or release retarding coating may take the form of an erodible polymer (e.g. a maleic anhydride polymer) which erodes substantially continuously as the dosage form passes through the gastrointestinal tract.

[0341] Compositions for topical use include ointments, creams, sprays, patches, gels, drops and inserts (e.g., intraocular inserts). Such compositions can be formulated according to known methods.

[0342] Compositions for parenteral administration are typically provided as sterile aqueous or oily solutions or fine suspensions, or may be provided in finely divided sterile powder form for extemporaneous constitution with sterile water for injection.

[0343] Examples of formulations for rectal or vaginal administration include pessaries and suppositories which may be formed, for example, from a moldable or waxy material containing the active compound.

[0344] Compositions for administration by inhalation can take the form of an inhalable powder composition or a liquid or powder spray and can be administered in standard form using a powder inhaler or aerosol dispensing device. Such devices are well known. For administration by inhalation, powdered formulations typically contain a combination of a dihydrotetrabenazine isomer, or a pharma- ceutically acceptable salt thereof, together with an inert solid powdered diluent (e.g., lactose).

[0345] The dihydrotetrabenazine isomers and their respective salts may be formulated separately and used in combination, or they may be formulated together. When formulated together, they may be provided as a mixture to which one or more pharmaceutical excipients are added prior to processing to form a pharmaceutical composition such as a unit dosage form (e.g., compressed to form a tablet or filled into a capsule). Alternatively, they may be added separately to an excipient or mixture of excipients and processed together. In a further alternative, at least some of the dihydrotetrabenazine isomers may be formulated separately into different granules, pellets, microbeads, or minitablets, which may then be combined and processed to provide a pharmaceutical composition (e.g., by filling into a capsule or compressing to form a tablet). As another alternative, different isomers of the dihydrotetrabenazine isomers may be contained within different layers in a multi-layer tablet.

[0346] Particular pharmaceutical compositions of the invention are compositions selected from: ·Sublingual composition; ·Intranasal; pellets or tablets formulated to provide release kinetics corresponding to a zero-order release of the active compound; Pellets or tablets formulated to provide an initial fast release of active compound followed by a constant rate of release (zero order); pellets or tablets formulated to provide a mixture of first-order and zero-order release of the active compound; and Pellets or tablets formulated to provide a combination of zero order and first order release of the active compound; and optionally higher order release of the active compound selected from second order, third order and fourth order release and combinations thereof.

[0347] Pellets and tablets formulated to provide release kinetics of the type defined above can be prepared according to methods well known to those skilled in the art, for example as described in Remington's Pharmaceutical Sciences (ibid.) and "Remington - The Science and Practice of Pharmacy, 21st Edition, 2006, ISBN 0-7817-4673-6.

[0348] The combinations of the invention will generally be presented in pharmaceutical unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity, as described above.

[0349] The combinations of the present invention are administered to a subject (patient) in need thereof (eg, a human or animal patient), as described above, in an amount sufficient to achieve the desired therapeutic effect. [Brief description of the drawings]

[0350] [Figure 1] FIG. 1 shows the mean total distance traveled in amphetamine-induced rats treated with vehicle (with or without amphetamine induction), (−)-α-dihydrotetrabenazine at a dose of 2.5 mg / kg, and risperidone at a dose of 1 mg / kg, as described in Example 2, Study 1 below.

[0351] [Diagram 2] FIG. 2 shows the average total stereotypic behavior by rats treated with vehicle (with or without amphetamine induction) and (−)-α-dihydrotetrabenazine at a dose of 2.5 mg / kg, and risperidone at a dose of 1 mg / kg in amphetamine-induced rats, as described in Example 2, Study 1 below.

[0352] [Diagram 3]FIG. 3 shows the mean total distance traveled by rats treated with vehicle (with or without amphetamine challenge) and (+)-α-dihydrotetrabenazine at doses of 0.1 mg / kg and 0.25 mg / kg, and risperidone at a dose of 1 mg / kg in amphetamine-challenged rats, as described in Example 2, Study 2 below.

[0353] [Figure 4] FIG. 4 shows the average total stereotypic behavior by rats treated with vehicle (with or without amphetamine induction) and (+)-α-dihydrotetrabenazine at doses of 0.1 mg / kg and 0.25 mg / kg, and risperidone at a dose of 1 mg / kg in amphetamine-induced rats, as described in Example 2, Study 2 below.

[0354] [Diagram 5] FIG. 5 shows the mean total distance traveled in amphetamine-induced rats treated with vehicle (with or without amphetamine induction) and (-)-α-dihydrotetrabenazine at a dose of 2 mg / kg, a combination of (+)-α-dihydrotetrabenazine at a dose of 2 mg / kg and (-)-α-dihydrotetrabenazine at a dose of 2 mg / kg, and risperidone at a dose of 1 mg / kg, as described in Example 2, Study 3 below.

[0355] [Figure 6] FIG. 6 shows the mean total stereotypic behavior of rats treated with vehicle (with or without amphetamine induction) and (-)-α-dihydrotetrabenazine at a dose of 2 mg / kg, a combination of (+)-α-dihydrotetrabenazine at a dose of 2 mg / kg and (-)-α-dihydrotetrabenazine at a dose of 2 mg / kg, and risperidone at a dose of 1 mg / kg in amphetamine-induced rats, as described in Example 2, Study 3 below.

[0356] [Figure 7]FIG. 7 shows the mean total distance traveled in amphetamine-induced rats treated with vehicle (with or without amphetamine induction) and combinations of (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in various ratios, and risperidone at a dose of 1 mg / kg, as described in Example 2, Study 4 below.

[0357] [Figure 8] FIG. 8 shows the mean total stereotypic behavior of amphetamine-induced rats treated with vehicle (with or without amphetamine induction) and combinations of (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in various ratios, and risperidone at a dose of 1 mg / kg, as described in Example 2, Study 4 below.

[0358] [Figure 9] FIG. 9 shows the mean total distance traveled in amphetamine-induced rats treated with vehicle (with or without amphetamine induction), (+)-β-dihydrotetrabenazine, and a combination of (+)-α-dihydrotetrabenazine and (+)-β-dihydrotetrabenazine, as described in Example 2, Study 5 below.

[0359] [Figure 10] FIG. 10 shows the mean total stereotypic behavior of rats treated with vehicle (with or without amphetamine challenge), (+)-β-dihydrotetrabenazine, and a combination of (+)-α-dihydrotetrabenazine and (+)-β-dihydrotetrabenazine in amphetamine-challenged rats, as described in Example 2, Study 5 below.

[0360] [Figure 11]FIG. 11 shows the mean total distance traveled in amphetamine-induced rats treated with vehicle (with or without amphetamine induction), (+)-α-dihydrotetrabenazine alone, (+)-α-dihydrotetrabenazine in combination with (-)-β-dihydrotetrabenazine, (+)-β-dihydrotetrabenazine in combination with (-)-α-dihydrotetrabenazine, (+)-β-dihydrotetrabenazine in combination with (-)-β-dihydrotetrabenazine, and (+)-α-dihydrotetrabenazine in combination with (+)-β-dihydrotetrabenazine, as described in Example 2, Study 6 below.

[0361] [Figure 12] FIG. 12 shows stereotypic behavior (distance over time) in amphetamine-induced rats treated with vehicle (with or without amphetamine induction), (+)-α-dihydrotetrabenazine alone, (+)-α-dihydrotetrabenazine in combination with (-)-β-dihydrotetrabenazine, (+)-β-dihydrotetrabenazine in combination with (-)-α-dihydrotetrabenazine, (+)-β-dihydrotetrabenazine in combination with (-)-β-dihydrotetrabenazine, and (+)-α-dihydrotetrabenazine in combination with (+)-β-dihydrotetrabenazine, as described in Example 2, Study 6 below. EXAMPLES

[0362] The following non-limiting examples illustrate the synthesis and properties of the compositions of the present invention.

[0363] Example 1 Investigation into the nature of dihydrotetrabenazine metabolites formed following administration of tetrabenazine to human subjects. A pharmacokinetic study was conducted to determine plasma concentrations of + / -α and + / -β dihydrotetrabenazine in healthy adult male volunteers after single and multiple oral administration of a 25 mg tablet once daily in the fasted state. The data are summarized below.

[0364] Table 1 summarizes the pharmacokinetic data obtained following a single oral dose of tetrabenazine (fasted, N = 08) at the 25 mg dose level. Table 1 [Table 1]

[0365] Table 2 summarizes the pharmacokinetic data obtained following repeated oral administration of tetrabenazine at the 25 mg dose level (fasted, N = 07). Table 2 [Table 2]

[0366] The data presented in Tables 1 and 2 demonstrate that in humans, the major metabolites are the (-)-α-dihydrotetrabenazine isomer, which is essentially the active component as a VMAT2 binder, and the (+)-β-dihydrotetrabenazine isomer, which is significantly less active than the (+)-α-dihydrotetrabenazine isomer. (-)-β-Dihydrotetrabenazine and (+)-α-dihydrotetrabenazine were shown to be minor metabolites.

[0367] The data suggest that (+)-α-dihydrotetrabenazine is not a major contributor to the therapeutic properties of tetrabenazine. Conversely, it appears that (+)-α-dihydrotetrabenazine may make a relatively minor contribution to the therapeutic properties of tetrabenazine.

[0368] Example 2 Examination of the effects of a combination of (+)-.ALPHA.-dihydrotetrabenazine and (-)-.ALPHA.-dihydrotetrabenazine on spontaneous and stereotypic movement in rats. The effects of a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine on locomotor activity and stereotypy in rats were examined and compared with the effects of the individual (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine isomers.

[0369] Materials and Methods equipment Open Field Arena, Med Associates Inc. Plastic syringe 1ml, Terumo Ref: SS-01T1 Animal Feeding Needle 15G, Instech Solomon, Cat:72-4446 Sartorius Mechatronics Scale A22101, Sartorius Weighting Technology, Germany Needle 27G Terumo Myjector, 0,5ml, Ref:8300010463 Plastic Syringe 3ml, Soft-Ject, Ref:8300005761 BD Microtainer K2EDTA Tube Ref:365975 Matrix 0, 75ml, Alphanum Tubes, Thermo Scientific, Ref: 4274 Microplate Devices, Uniplate 24 well, 10ml, Ref:734‐1217 Thermo Electron Corp. Heraeus Fresco 17, refrigerated centrifuge

[0370] Animals All animal experiments were performed in accordance with the US National Institutes of Health (NIH) guidelines for the care and use of laboratory animals and approved by the National Animal Experiment Board, Finland. Male CD mice (Charles River Laboratories, Germany) weighing in the range of 200–250 g (165–200 g on arrival) were used for the experiments. Animals were housed at standard temperature (22 ± 1 °C) in a light-controlled environment (lights on from 7 am to 8 pm) with free access to food and water.

[0371] method The spontaneous movement of rats was tested in an open field arena. The open field test was performed under normal lighting evenly distributed in the test chamber during the rat's light cycle. The rat's path was recorded by an activity monitor (Med. Associates Inc.).

[0372] Vehicle, amphetamine, (+)-α-DHTBZ, (-)-α-DHTBZ, (+)-β-DHTBZ, (-)-β-DHTBZ or risperidone were administered before the LMA test. Rats were placed in the center of the arena and paths were recorded for 30 min. After the 30 min test, vehicle or amphetamine was administered, rats were placed in the center of the arena and paths were recorded for 60 min, for a total test time of 90 min.

[0373] Endpoints, Blood Samples and Tissue Processing Within 10 minutes of the end of the study, animals were euthanized by an overdose of CO2. Terminal blood samples were collected by cardiac puncture from all compound-treated rats from each group except vehicle rats. 0.5 ml of blood was collected with a syringe attached to an 18G needle and transferred into a pre-chilled K2-EDTA microtube. The EDTA microtube was inverted several times to mix the EDTA with the blood. The tubes were then immediately placed on wet ice and centrifuged (Heraeus Fresco 17) (9.6x 1000 G / 10x 1000 RPM, +4°C, 2 minutes) within 10-15 minutes of collection, and 200 μl of plasma was collected into a 96-tube plate (Matrix Technologies ScreenMates 0.75 ml Alphaundic Round-Bottom Storage tubes, PP) on dry ice according to the sample map.

[0374] After blood collection, the neck was dislocated at the base of the skull, and the brains were harvested and weighed. Brain weights were recorded and the brains were frozen on dry ice in 24-well plates.

[0375] Plasma and brain samples were stored on dry ice at -80°C until sent for analysis.

[0376] Test 1 The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t = 0 min) and amphetamine (t = 30 min) Group 3: 10 rats treated with (-)-α-DHTBZ 2.5 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 4: 10 rats treated with risperidone 1 mg / kg (t = 0 min) and amphetamine (t = 30 min).

[0377] result 1. Distance traveled Rats administered either vehicle, (-)-α-DHTBZ 2.5 mg / kg or risperidone 1 mg / kg were subjected to LMA testing for 30 min and then 60 min after vehicle or amphetamine challenge. Resulting locomotor activity was assessed in 3 min bins and summed over the test period. The normalized total distance traveled over the test period is shown in Figure 1.

[0378] Vehicle-amphetamine and (-)-α-DHTBZ 2.5 mg / kg were significantly different when compared to the vehicle-vehicle group. Vehicle-vehicle and risperidone 1 mg / kg were significantly different when compared to the vehicle-amphetamine group.

[0379] 2. Stereotypic behavior Rats administered either vehicle, (-)-α-DHTBZ 2.5 mg / kg, or risperidone 1 mg / kg were subjected to LMA testing for 30 min and then 60 min after vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3 min bins and as a sum over the test period. The normalized total stereotypic behavior over the test period is shown in Figure 2.

[0380] Vehicle-amphetamine and (-)-α-DHTBZ 2.5 mg / kg were significantly different when compared to the vehicle-vehicle group. Vehicle-vehicle and risperidone 1 mg / kg were significantly different when compared to the vehicle-amphetamine group.

[0381] conclusion In this study, we evaluated the effects of (-)-α-DHTBZ at a dose of 2.5 mg / kg and risperidone at a dose of 1 mg / kg on amphetamine-induced locomotor activity in male CD rats.

[0382] (-)-α-DHTBZ at a dose of 2.5 mg / kg did not reduce locomotor activity or stereotyped behavior when compared to the vehicle-amphetamine group. Rats receiving (-)-α-DHTBZ at a dose of 2.5 mg / kg were less interested in what was going on around them. Rats receiving (-)-α-DHTBZ were equally active when compared to vehicle-amphetamine-treated animals, suggesting that (-)-α-DHTBZ does not have the same sedative effect as risperidone.

[0383] Test 2 The effects of (+)-α-dihydrotetrabenazine (0.1 mg / kg to 0.25 mg / kg) and risperidone (1 mg / kg) on ​​stereotypic behavior and distance traveled were examined in rats.

[0384] The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t = 0 min) and amphetamine (t = 30 min) Group 3: 10 rats treated with (+)-α-DHTBZ 0.1 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 4: 10 rats treated with (+)-α-DHTBZ 0.25 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 5: 10 rats treated with risperidone 1 mg / kg (t = 0 min) and amphetamine (t = 30 min).

[0385] result 1. Distance traveled Rats administered either vehicle, (+)-α-DHTBZ 0.1 mg / kg, (+)-α-DHTBZ 0.25 mg / kg, or risperidone 1 mg / kg were first subjected to a 30-min and then a 60-min LMA test following vehicle or amphetamine challenge. Resulting locomotor activity was assessed in 3-min bins and summed over the test period. The normalized total distance traveled over the test period is shown in Figure 3.

[0386] Vehicle-vehicle, (+)-α-DHTBZ 0.25 mg / kg, and risperidone 1 mg / kg were significantly different when compared with the vehicle-amphetamine group.

[0387] 2 Stereotypic behavior Rats administered either vehicle, (+)-α-DHTBZ 0.1 mg / kg, (+)-α-DHTBZ 0.25 mg / kg, or risperidone 1 mg / kg were first subjected to a 30-min and then a 60-min LMA test following vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3-min bins and as a sum over the test period. The normalized total stereotypic behavior over the test period is shown in Figure 4.

[0388] When compared with the vehicle-amphetamine group, vehicle-vehicle, (+)-α-DHTBZ 0.1 mg / kg, (+)-α-DHTBZ 0.25 mg / kg and risperidone 1 mg / kg were significantly different.

[0389] conclusion In this study, we evaluated the effects of (+)-α-DHTBZ at doses of 0.1 mg / kg and 0.25 mg / kg and risperidone at a dose of 1 mg / kg on amphetamine-induced locomotor activity in male CD rats.

[0390] (+)-α-DHTBZ 0.25 mg / kg and risperidone 1 mg / kg resulted in lower locomotor activity when compared to the vehicle-amphetamine group. Both tested doses of (+)-α-DHTBZ and risperidone 1 mg / kg resulted in reduced stereotypic behavior when compared to the vehicle-amphetamine group.

[0391] Test 3 The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t = 0 min) and amphetamine (t = 30 min) Group 3: 10 rats treated with (+)-α-DHTBZ 2 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 4: 10 rats treated with (+)-α-DHTBZ 2 mg / kg and (-)-α-DHTBZ 2 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 5: 10 rats treated with risperidone 1 mg / kg (t = 0 min) and amphetamine (t = 30 min).

[0392] result 1. Distance traveled Rats administered either vehicle, a combination of (+)-α-DHTBZ 2 mg / kg, (-)-α-DHTBZ 2 mg / kg and (+)-α-DHTBZ 2 mg / kg or risperidone 1 mg / kg were first subjected to a 30-min and then a 60-min LMA test following vehicle or amphetamine challenge. The resulting locomotor activity was assessed in 3-min bins and summed over the test period. The normalized total distance traveled over the test period is shown in Figure 5.

[0393] Vehicle-amphetamine was significantly different when compared with the vehicle-vehicle group. Vehicle-vehicle, (+)-α-DHTBZ 2 mg / kg, the combination of (-)-α-DHTBZ 2 mg / kg and (+)-α-DHTBZ 2 mg / kg, and the combination of risperidone 1 mg / kg were significantly different when compared with the vehicle-amphetamine group.

[0394] 2 Stereotypic behavior Rats administered either vehicle, (+)-α-DHTBZ 2 mg / kg, a combination of (-)-α-DHTBZ 2 mg / kg and (+)-α-DHTBZ 2 mg / kg, or risperidone 1 mg / kg were first subjected to a 30-min and then a 60-min LMA test after vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3-min bins and summed over the test period. The normalized total stereotypic behavior over the test period is shown in Figure 6.

[0395] Compared with the vehicle-amphetamine group, vehicle-vehicle, (+)-α-DHTBZ 2 mg / kg, the combination of (-)-α-DHTBZ 2 mg / kg and (+)-α-DHTBZ 2 mg / kg, and risperidone 1 mg / kg were significantly different.

[0396] conclusion In this study, we evaluated the effects of compounds (+)‐α‐DHTBZ at a dose of 2 mg / kg, the combination of (+)‐α‐DHTBZ and (−)‐α‐DHTBZ at a dose of 2 mg / kg, and risperidone at a dose of 1 mg / kg on amphetamine‐induced locomotor activity in male CD rats.

[0397] The test doses of (+)-α-DHTBZ, the combination of (+)-α-DHTBZ and (-)-α-DHTBZ at a dose of 2 mg / kg, and risperidone at 1 mg / kg resulted in lower locomotor activity when compared to the vehicle-amphetamine group.The test doses of (+)-α-DHTBZ, the combination of (+)-α-DHTBZ and (-)-α-DHTBZ at a dose of 2 mg / kg, and risperidone at 1 mg / kg resulted in reduced stereotypical behavior when compared to the vehicle-amphetamine group.

[0398] Amphetamine-induced locomotor activity was less in rats treated with a combination of (+)-α-DHTBZ and (−)-α-DHTBZ than in rats treated with (+)-α-DHTBZ alone, although the (−)-α-isomer has been shown to reduce induced locomotor activity only slightly, if at all.

[0399] Test 4 The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t=0 min) and amphetamine (t=30 min) Group 3: 10 rats treated with (+)-α-DHTBZ 0.5 mg / kg (t = 0 min) and (-)-α-DHTBZ 0.5 mg / kg and amphetamine (t = 30 min). Group 4: 10 rats treated with (+)-α-DHTBZ 1.0 mg / kg (t = 0 min) and (-)-α-DHTBZ 0.5 mg / kg and amphetamine (t = 30 min). Group 5: 10 rats treated with (+)-α-DHTBZ 1.0 mg / kg (t = 0 min) and (-)-α-DHTBZ 1.0 mg / kg and amphetamine (t = 30 min). Group 6: 10 rats treated with (+)-α-DHTBZ 1.5 mg / kg (t = 0 min) and (-)-α-DHTBZ 1.0 mg / kg and amphetamine (t = 30 min).

[0400] result 1. Distance traveled Rats administered either vehicle, a combination of (+)-α-DHTBZ 0.5 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, a combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, a combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 1 mg / kg, or a combination of (+)-α-DHTBZ 1.5 mg / kg and (-)-α-DHTBZ 1 mg / kg were subjected to LMA testing for 30 min and then 60 min after vehicle or amphetamine challenge. The resulting locomotor activity was assessed in 3 min bins and summed over the test period. The normalized total distance traveled over the test period is shown in Figure 7.

[0401] Compared with the vehicle-amphetamine group, vehicle-vehicle, (+)-α-DHTBZ, the combination of (+)-α-DHTBZ 0.5 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, the combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, the combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 1 mg / kg, and the combination of (+)-α-DHTBZ 1.5 mg / kg and (-)-α-DHTBZ 1 mg / kg were significantly different.

[0402] 2 Stereotypic behavior Rats administered vehicle, a combination of (+)-α-DHTBZ 0.5 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, a combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, a combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 1 mg / kg, or a combination of (+)-α-DHTBZ 1.5 mg / kg and (-)-α-DHTBZ 1 mg / kg were first subjected to a 30-min and then a 60-min LMA test following vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3-min bins and as a sum over the test period. The normalized total stereotypic behavior over the test period is shown in Figure 8.

[0403] The combination of (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 0.5 mg / kg was significantly different when compared to the vehicle-vehicle group. The combinations of vehicle-vehicle, (+)-α-DHTBZ 0.5 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 0.5 mg / kg, (+)-α-DHTBZ 1 mg / kg and (-)-α-DHTBZ 1 mg / kg, and (+)-α-DHTBZ 1.5 mg / kg and (-)-α-DHTBZ 1 mg / kg were significantly different when compared to the vehicle-amphetamine group.

[0404] conclusion In this study, we evaluated the effects of dose combinations of (+)‐α‐DHTBZ and (−)‐α‐DHTBZ at 0.5 mg / kg + 0.5 mg / kg, 1 mg / kg + 0.5 mg / kg, 1 mg / kg + 1 mg / kg, and 1.5 mg / kg + 1 mg / kg on amphetamine‐induced locomotor activity in male CD rats.

[0405] Combinations of (+)-α-DHTBZ and (-)-α-DHTBZ at all doses tested and risperidone at 1 mg / kg resulted in lower locomotor activity when compared to the vehicle-amphetamine group. Combinations of (+)-α-DHTBZ and (-)-α-DHTBZ at all doses tested and risperidone at 1 mg / kg resulted in reduced stereotypic behavior when compared to the vehicle-amphetamine group.

[0406] There appears to be an interaction between (+)-α-DHTBZ and (-)-α-DHTBZ that affects the ability of (+)-α-DHTBZ to block amphetamine-induced hyperactivity.

[0407] Comparing the data from rats receiving a combination of (+)-α-DHTBZ 1 mg / kg and (−)-α-DHTBZ 0.5 mg / kg with those receiving a combination of (+)-α-DHTBZ 1 mg / kg and (−)-α-DHTBZ 1 mg / kg, demonstrating the lack of efficacy of the isolated (−)-α isomer, it would not be expected that increasing the amount of the (−)-α isomer in the combination treatment would result in a decrease in locomotor activity in the test rats.

[0408] Test 5 The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t=0 min) and amphetamine (t=30 min) Group 3: 10 rats treated with (+)-β-DHTBZ 2.5 mg / kg (t=0 min) and amphetamine (t=30 min) Group 4: 10 rats treated with (+)-β-DHTBZ 5 mg / kg (t = 0 min) and amphetamine (t = 30 min) Group 5: 10 rats treated with (+)-β-DHTBZ 2.5 mg / kg and (+)-α-DHTBZ 2.5 mg / kg (t=0 min) and amphetamine (t=30 min).

[0409] result 1. Distance traveled Rats administered either vehicle, (+)-β-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 5 mg / kg, or (+)-β-DHTBZ 2.5 mg / kg and (+)-α-DHTBZ 2.5 mg / kg were subjected to the LMA test for 30 minutes and then 60 minutes after vehicle or amphetamine challenge. The resulting locomotor activity was assessed in 3-minute bins and summed over the test period. The normalized total distance traveled over the test period is shown in FIG. 9.

[0410] The combinations vehicle-vehicle, (+)-β-DHTBZ 2.5 mg / kg and (+)-β-DHTBZ 5 mg / kg were significantly different when compared to the vehicle-vehicle group. The combinations vehicle-vehicle, (+)-β-DHTBZ 2.5 mg / kg and (+)-α-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 2.5 mg / kg and (+)-β-DHTBZ 5 mg / kg were significantly different when compared to the vehicle-vehicle group.

[0411] 2 Stereotypic behavior Rats administered either vehicle, (+)-β-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 5 mg / kg, or (+)-β-DHTBZ 2.5 mg / kg and (+)-α-DHTBZ 2.5 mg / kg were subjected to the LMA test for 30 min and then 60 min after vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3 min bins and summed over the test period. The normalized total stereotypic behavior over the test period is shown in FIG. 10.

[0412] Vehicle-amphetamine, (+)-β-DHTBZ 2.5 mg / kg, and (+)-β-DHTBZ 5 mg / kg were significantly different when compared to the vehicle-vehicle group. The combinations (+)-β-DHTBZ 2.5 mg / kg and (+)-α-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 2.5 mg / kg, and (+)-β-DHTBZ 5 mg / kg were significantly different when compared to the vehicle-amphetamine group and vehicle-vehicle group.

[0413] Test 6 The animals were grouped as follows: Group 1: 10 rats treated with vehicle (t=0 min) and vehicle (t=30 min) Group 2: 10 rats treated with vehicle (t=0 min) and amphetamine (t=30 min) Group 3: 10 rats treated with (+)-α-DHTBZ 1 mg / kg (t = 0 min) and amphetamine (t = 30 min). Group 4: 10 rats treated with (+)-α-DHTBZ 1 mg / kg + (-)-α-DHTBZ 1 mg / kg (t = 0 min); and amphetamine (t = 30 min). Group 5: 10 rats treated with (+)-α-DHTBZ 1 mg / kg + (-)-β-DHTBZ 1 mg / kg (t = 0 min and t = 30 min) amphetamine Group 6: 10 rats treated with (+)-β-DHTBZ 1 mg / kg + (-)-α-DHTBZ 1 mg / kg (t = 0 min) and amphetamine (t = 30 min) Group 7: 10 rats treated with (+)-β-DHTBZ 1 mg / kg + (-)-β-DHTBZ 1 mg / kg (t = 0 min); and amphetamine (t = 30 min). Group 8: 10 rats treated with (+)-α-DHTBZ 1 mg / kg + (+)-β-DHTBZ 1 mg / kg (t = 0 min); and amphetamine (t = 30 min). Group 9: 10 rats treated with risperidone 1 mg / kg (t=0 min) and amphetamine (t=30 min)

[0414] result 1. Distance traveled Rats administered either vehicle or dihydrotetrabenazine were subjected to the LMA test for 30 and then 60 minutes after vehicle or amphetamine challenge. The resulting locomotor activity was assessed in 3 minute bins and summed over the test period. The total unnormalized distance traveled over the test period is shown in FIG. 11.

[0415] When compared to the vehicle-vehicle group, the vehicle-amphetamine, (+)-β-DHTBZ 1 mg / kg + (-)-α-DHTBZ 1 mg / kg, and (+)-β-DHTBZ 1 mg / kg + (-)-β-DHTBZ 1 mg / kg groups were significantly different. When compared to the vehicle-amphetamine group, the vehicle-vehicle group was significantly different, as were groups 1 and 3-9.

[0416] 2 Stereotypic behavior Rats administered either vehicle or dihydroterabenazine were subjected to the LMA test for 30 minutes and then 60 minutes after vehicle or amphetamine challenge. The resulting stereotypic behavior was assessed in 3 minute bins and summed over the test period. The total unnormalized stereotypic behavior over the test period is shown in FIG. 12.

[0417] When compared to the vehicle-vehicle group, the vehicle-amphetamine, (+)-β-DHTBZ 1 mg / kg + (-)-α-DHTBZ 1 mg / kg, and (+)-β-DHTBZ 1 mg / kg + (-)-β-DHTBZ 1 mg / kg groups were significantly different. When compared to the vehicle-amphetamine group, the vehicle-vehicle group was significantly different, as were groups 1 and 3-9.

[0418] comment Study 1 evaluated the effects of (-)-α-DHTBZ at a dose of 2.5 mg / kg and risperidone at a dose of 1 mg / kg on amphetamine-induced locomotor activity in male CD rats.

[0419] (-)-α-DHTBZ at a dose of 2.5 mg / kg did not result in decreased locomotor activity or decreased stereotypic behavior when compared to the vehicle-amphetamine group. Rats receiving (-)-α-DHTBZ at a dose of 2.5 mg / kg were less interested in what was going on around them. Rats receiving (-)-α-DHTBZ were equally active when compared to vehicle-amphetamine-treated animals, suggesting that (-)-α-DHTBZ does not have the same effects on behavior as risperidone.

[0420] In study 2, the effects of (+)-α-DHTBZ 0.1 mg / kg and 0.25 mg / kg, and risperidone 1 mg / kg on amphetamine-induced locomotor activity in male CD rats were evaluated.

[0421] (+)-α-DHTBZ at 0.25 mg / kg and risperidone 1 mg / kg resulted in lower locomotor activity when compared to the vehicle-amphetamine group. (+)-α-DHTBZ and risperidone 1 mg / kg at both doses tested resulted in reduced stereotypic behavior when compared to the vehicle-amphetamine group.

[0422] Study 3 evaluated the effects of a 2 mg / kg dose of (+)‐α‐DHTBZ, a 2 mg / kg dose of the combination of (+)‐α‐DHTBZ and (−)‐α‐DHTBZ, and a 1 mg / kg dose of risperidone on amphetamine-induced locomotor activity in male CD rats.

[0423] (+)-α-DHTBZ at all doses tested, the combination of (+)-α-DHTBZ and (-)-α-DHTBZ at 2 mg / kg, and risperidone at 1 mg / kg reduced locomotor activity compared to the vehicle-amphetamine group.(+)-α-DHTBZ at all doses tested, the combination of (+)-α-DHTBZ and (-)-α-DHTBZ at 2 mg / kg, and risperidone at 1 mg / kg reduced stereotypic behavior compared to the vehicle-amphetamine group.

[0424] Rats treated with a combination of (+)‐α‐DHTBZ and (−)‐α‐DHTBZ showed less amphetamine‐induced locomotor activity than rats treated with (+)‐α‐DHTBZ alone, even though the (−)‐α‐isomer has been shown to produce little, if any, reduction in induced locomotor activity.

[0425] Study 4 evaluated the effects of combinations of (+)‐α‐DHTBZ and (−)‐α‐DHTBZ at doses of 0.5 mg / kg + 0.5 mg / kg, 1 mg / kg + 0.5 mg / kg, 1 mg / kg + 1 mg / kg and 1.5 mg / kg + 1 mg / kg on amphetamine‐induced locomotor activity in male CD rats.

[0426] Combinations of (+)-α-DHTBZ and (-)-α-DHTBZ in all tested combinations and risperidone 1 mg / kg resulted in lower locomotor activity when compared to the vehicle-amphetamine group. Combinations of (+)-α-DHTBZ and (-)-α-DHTBZ in all tested doses and risperidone 1 mg / kg resulted in reduced stereotypic behavior when compared to the vehicle-amphetamine group.

[0427] Considering the lack of efficacy of the isolated (-)-α-DHTBZ, comparing the data for rats receiving a combination of (+)-α-DHTBZ at a dose of 1 mg / kg and (-)-α-DHTBZ at a dose of 0.5 mg / kg with that for rats receiving a combination of (+)-α-DHTBZ at a dose of 1 mg / kg and (-)-α-DHTBZ at a dose of 1 mg / kg, it was surprising that increasing the amount of the (-)-α-isomer in the combination treatment led to a decrease in locomotor activity in the rats tested.

[0428] Study 5 evaluated the effects of (+)-β-DHTBZ 2.5 mg / kg and 5 mg / kg doses, and the combination of (+)-α-DHTBZ 2.5 mg / kg and (+)-β-DHTBZ 2.5 mg / kg doses, on amphetamine-induced locomotor activity in male CD rats.

[0429] (+)-β-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 5 mg / kg, and the combination of (+)-α-DHTBZ 2.5 mg / kg with (+)-β-DHTBZ 2.5 mg / kg reduced locomotor activity when compared to the vehicle-amphetamine group. (+)-β-DHTBZ 2.5 mg / kg, (+)-β-DHTBZ 5 mg / kg, and the combination of (+)-α-DHTBZ 2.5 mg / kg with (+)-β-DHTBZ 2.5 mg / kg also reduced stereotypic behavior when compared to the vehicle-amphetamine group. Rats administered (+)‐β‐DHTBZ at a dose of 5 mg / kg were less interested in what was going on around them, and rats receiving (+)‐β‐DHTBZ 5 mg / kg were observed to have tense limbs and partially lacked their righting reflex at the end of the test.

[0430] In study 6, the effects of (+)-α-DHTBZ 1 mg / kg dose, the combination of (+)-α-DHTBZ 1 mg / kg dose + (-)-α-DHTBZ 1 mg / kg dose, the combination of (+)-α-DHTBZ 1 mg / kg dose + (-)-β-DHTBZ 1 mg / kg dose, the combination of (+)-β-DHTBZ 1 mg / kg dose + (-)-α-DHTBZ 1 mg / kg dose, the combination of (+)-β-DHTBZ 1 mg / kg dose + (-)-β-DHTBZ 1 mg / kg dose, the combination of (+)-α-DHTBZ 1 mg / kg dose + (-)-β-DHTBZ 1 mg / kg dose, the combination of (+)-α-DHTBZ 1 mg / kg dose + (+)-β-DHTBZ 1 mg / kg dose, and risperidone 1 mg / kg dose on amphetamine-induced locomotor activity in male CD rats were evaluated.

[0431] Vehicle, risperidone and all dihydrotetrabenazine containing treatments resulted in lower locomotor activity and reduced stereotypic behavior when compared to the vehicle-amphetamine group.

[0432] Results from six trials indicate that (+)-β-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and the combination of (+)-α-dihydrotetrabenazine are useful in treating movement disorders.

[0433] Equivalent It will be readily apparent that numerous modifications and variations can be made to the specific embodiments of the invention described above without departing from the underlying principles of the invention, and all such modifications and variations are intended to be covered by this application.

Claims

1. A unit dosage form for the treatment of hyperkinetic movement disorder comprising 5 mg to 80 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient, wherein the (+)-β-dihydrotetrabenazine is accompanied by no more than 20% by weight of any other dihydrotetrabenazine isomer relative to the (+)-β-dihydrotetrabenazine.

2. 2. The unit dosage form of claim 1, wherein the (+)-β-dihydrotetrabenazine is associated with 1% or less of any other dihydrotetrabenazine isomer.

3. 3. A unit dosage form according to claim 1 or 2, comprising 5 mg to 60 mg of (+)-β-dihydrotetrabenazine, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

4. The unit dosage form according to any one of claims 1 to 3, which is in the form of a capsule, tablet, solution, syrup, suspension or gel.

5. A pharmaceutical composition for the treatment of hyperkinetic movement disorders, comprising 5 mg to 80 mg of (+)-β-dihydrotetrabenazine or a pharma- ceutically acceptable salt thereof, wherein the (+)-β-dihydrotetrabenazine has an isomeric purity of at least 80%.

6. The pharmaceutical composition of claim 5, comprising 5 mg to 60 mg of (+)-β-dihydrotetrabenazine.

7. 7. The unit dosage form according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 or 6, wherein the hyperkinetic movement disorder is selected from Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, dystonia and Tourette's syndrome.

8. A unit dosage form described in any one of claims 1 to 4 or a pharmaceutical composition described in claim 5 or 6, wherein the hyperkinetic movement disorder is Huntington's disease.

9. A unit dosage form described in any one of claims 1 to 4 or a pharmaceutical composition described in claim 5 or 6, wherein the hyperkinetic movement disorder is Tourette's syndrome.

10. A unit dosage form described in any one of claims 1 to 4 or a pharmaceutical composition described in claim 5 or 6, wherein the hyperkinetic movement disorder is tardive dyskinesia.

Citation Information

Patent Citations

  • Dihydrotetrabenazines and pharmaceutical compositions containing them

    JP2007522193A

  • Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease

    JP2009501202A

  • Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-2-ol compounds and related methods

    JP2010509366A

  • VMAT2 inhibitors for the treatment of hyperkinetic movement disorders

    WO2015171802A1